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ABSTRACT 
 
 
Despite widespread vaccination, Bordetella pertussis, the causative agent of whooping 
cough, is still a threat to global health. One cause of pertussis reemergence observed in 
many countries is ineffective immunity generated by the current acellular pertussis (aP) 
vaccines. Interestingly, recent studies have shown that TLR stimulating agents can 
enhance aP vaccine induced immunity. Type III secretion (T3S) system needle proteins 
from many gram-negative bacteria have been shown to be strong TLR agonists that 
induce NF-𝜅B/AP-1 signaling and promote inflammatory cytokine release from innate 
cells in vitro. In this study, we investigated the immune modulating properties of BscF, a 
purified T3S system needle protein from B. pertussis. In addition, we characterized the 
ability of BscF to enhance aP vaccine induced immunity. In the current study, we 
demonstrated that BscF is a strong TLR2 and TLR4 agonist that induced NF-𝜅B/AP-1 
activation and promoted inflammatory cytokine release, augmented by clathrin-
mediated endocytosis. In vivo, BscF immunization induced robust antibody responses, 
strong Th1 and Th17 responses from stimulated splenocytes, and provided modest 
protection against B. pertussis challenge. BscF also enhanced aP induced immunity and 
reduced lung bacterial burden in mice challenged with B. pertussis. These results 
demonstrate that BscF has considerable potential to be included in a next-generation B. 
pertussis aP vaccine.       
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CHAPTER I 
 
INTRODUCTION 
 
Bordetella Microbiology and History 
 
 The genus Bordetella, belonging to the Alcaligenaceae family, are comprised of 
10 genetically distinct species (1-3). B. pertussis is a Gram-negative, non-motile, aerobic 
coccobacillus that is typically grown at 37 ℃ on special Bordet-Gengou agar 
supplemented with blood and other growth factors. B. pertussis’s growth on blood 
supplemented medium is slow, requiring at least 3 days for colonies to appear. Within 
the genus Bordetella, the species can be differentiated, in part, by their hosts they infect 
as well as the symptoms reported during infection. B. pertussis is strictly a human 
pathogen (4-5) and was first thought as the sole cause of the prototypical whooping 
cough in humans. More recently, B. parapertussis, and B. holmesii have been identified 
to cause the prototypical whooping cough symptoms (6-11). While primarily thought of 
as a domestic animal pathogen i.e., cats and dogs (12-13), B. bronchiseptica has been 
isolated in rare events from immunocompromised or traumatized humans (14-16). 
Despite the ability of many Bordetella species to infect humans, B. pertussis still remains 
the most well characterized, and possess the greatest risk to overall global health.   
 When compared to many other infectious diseases, whooping cough is a fairly 
newly discovered pathogen. Pertussis-like symptoms and illness go back roughly 1,500 
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years when it was described by a Chinese medical scholar as “the cough of 100 days” 
(17-18). Fast forward to 1578 when Guillaume de Baillou characterized what was 
thought of today as the oldest pertussis outbreak among children in Paris (19). Recent 
evidence suggests that 3 epidemics of whooping cough occurred in Persia (present-day 
Iran) in the 15th and 16th century, likely indicating the earliest recorded epidemics of 
whooping cough in the world (20). Outbreaks of pertussis have also been reported in 
Europe during the 16th century, however the causative agent was not identified until 
much later. In 1906, B. pertussis was first identified as the causative agent of whooping 
cough by Jules Bordet and Octave Gengou (21), leading to Bordet winning the 1920 
Nobel Prize in Physiology or Medicine for his extensive body of work from developing 
culture medium necessary to grow B. pertussis to further characterization of B. pertussis 
as the causative agent of whooping cough. B. pertussis as it’s named today, was 
originally named Haemophilus pertussis, but the name was changed to honor one of its 
discoverers (22).   
Bordetella pertussis pathogenesis 
 As previously mentioned, B. pertussis is strictly a human pathogen (4-5). B. 
pertussis is pathogen that targets the upper respiratory tract is classically considered an 
extracellular pathogen. Despite its extracellular location within the respiratory tract, B. 
pertussis has been shown to invade ciliated epithelial cells as well as alveolar 
macrophages (23-25). B. pertussis is passed from human to human through inhalation of 
infected respiratory droplets (26-30). Upon inhalation, B pertussis enters and adheres to 
ciliated epithelial cells of the upper respiratory tract (26-31). B. pertussis is classified as a 
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toxin mediated disease that requires a coordinated effort from a number of virulence 
factors expressed by the bacteria. This coordinated virulence factor activation is 
initiated upon B. pertussis attachment, and further allows for B. pertussis dissemination 
to the lower respiratory tract (26-31). These virulence factors include toxins: pertussis 
toxin (PT), adenylate cyclase toxin (ACT), dermonecrotic toxin (DNT), and tracheal 
cytotoxin (TCT), as well as other structures including filamentous hemagglutinin (FHA), 
fimbriae (FIM), pertactin (PRN), the type three secretion (T3S) system, and 
lipopolysaccharide (LPS). These bvgAS virulence genes are controlled by the BvgAS two-
component regulatory system of B. pertussis and allows the bacteria to respond to 
changing environments (32-37). The importance of these virulence factors during 
infection are highlighted in a number of studies indicating that these virulence factors 
not only promote adhesion and invasion of ciliated epithelial cells, but also strongly 
influence the host’s innate and adaptive immune system often times at the expense of 
the host and to the benefit of the pathogen.     
B. pertussis virulence factors and host immune modulation 
pertussis toxin (PT) 
 PT is the most well characterized toxin and is the only B. pertussis antigen that is 
included in all formulations of current licensed acellular pertussis (aP) vaccines. PT is 
classified as an A-B toxin consisting of 5 subunits (S1 through S5). The A subunit (S1) is 
an ADP-ribosyltransferase while the B subunit is a pentameric ring structure (S2, S3, S5, 
and two S4 subunits) that mediates toxin binding to target cells through binding to 
glycosylated receptors (38-39). Once inside the cell, the holotoxin undergoes retrograde 
transport to the endoplasmic reticulum and the S1 subunit (the catalytic domain of PT) 
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is released into the cytosol (40). Once inside the cytosol, PT modifies intracellular 
signaling cascades through its ribosylation of the 𝛼 subunit of heterotrimeric G proteins. 
PT has been implicated in many secondary systemic complications that arise from B. 
pertussis infections because of its ability to bind glycosylated receptors, as well as its 
ability to modify G proteins; both glycosylated receptors and G proteins are expressed in 
many different tissues. The pleiotropic affects seen by PT range from paroxysms and 
neurological disturbance (41), lymphocytosis (42), hyperinsulinemia, hypoglycemia, as 
well as histamine sensitization (43) are the result of its enzymatic activity. In addition, PT 
as well as detoxified PT (dPT) can act as pattern associated molecular patterns (PAMPs) 
that bind and activate a group of pattern recognition receptors (PRRs) called toll-like 
receptors (TLRs), specifically TLR2 and TLR4 (44-46).  
 In addition to its enzymatic and immune stimulating activities, PT can modulate 
the host innate and adaptive immune response further limiting the ability of the host to 
respond to, and clear, a B. pertussis infection, as well as influence the surrounding 
environment by either promoting pro- or anti-inflammatory mechanisms. Many of these 
studies have been completed in PT-deficient B. pertussis strains. The contribution of PT 
to early stages of infection were elucidated as infection with a PT-deficient B. pertussis 
strain resulted in lower bacterial colonization as early as 24 hours post infection (47). In 
addition, it appears that PT suppresses early neutrophil influx into the lungs during B. 
pertussis infection through inhibition of neutrophil attracting chemokine release from 
resident cells within the lungs (47-50). PT has also been shown to target and inhibit 
airway macrophages in addition to neutrophils (51). PT also targets the adaptive 
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immune system by suppressing B. pertussis specific serum antibody levels during 
infection (52-53). Interestingly, the role of PT appears to evolve as the infection 
progresses. Early in infection, the primary role of PT is to down regulate host immunity, 
primarily through innate cell inhibition. However, at the peak of infection PT induces 
robust lung inflammation and pathology in mice (54). From these studies we can 
appreciate the importance and complicated role that PT plays during B. pertussis 
infection.       
Adenylate cyclase toxin (ACT) 
 ACT is another important B. pertussis specific toxin that is now recently been the 
focus of studies determining the usefulness of adding ACT to new aP vaccines. To date, 
ACT is not an antigen that is included in current aP vaccines. ACT is a member of the 
repeat in toxin family and is secreted from the cell via type I secretion. ACT possesses 
two functional C- and N-terminal domains that facilitate receptor binding on host cells 
and its catalytic adenylate cyclase activity, respectively (55). Once inside the host cell 
cytosol, the catalytic domain is activated by by calmodulin binding, facilitating the 
conversion of cellular ATP into cAMP and modifying intracellular signaling cascades (56). 
Given that both PT and ACT appear to modify intracellular signaling in similar manners, 
it was thought that these toxins may play redundant roles during infection.  ACT-
deficient B. pertussis strains showed reduced colonization ability; however, these strains 
were able to colonize the host for a short period of time but were unable to cause 
persistent infections (48). From these observations and the observations that PT-
deficient strains showed reduced ability to colonize early during infection, it is likely that 
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these two toxins have non-redundant roles in B. pertussis infections: PT facilitates early 
colonization while ACT is necessary for persistent infection (48).     
 Like PT, ACT also modulates the surrounding environment to facilitate infection. 
ACT has been shown to down regulate host immunity by inhibiting phagocytic cell 
trafficking, bactericidal activities, and pro-inflammatory cytokine release (57-58). ACT 
also has been shown to modulate the adaptive arm of the immune system during 
infection. T-helper (Th) cells, specifically Th1 and to a lesser extent Th17 cells, are 
important for resolution of B. pertussis infections. ACT directly targets T cell activation 
and differentiation to skew CD4+ T cells to a Th2 type phenotype (59); a T cell response 
that has shown to be non protective both animal and human models. ACT also polarizes 
the adaptive immune system to a Th17 type response by NLRP3 inflammasome 
activation and subsequent IL-1𝛽 production from murine dendritic cells (DC) (60). The 
pro-inflammatory role of ACT is controversial, but the importance of ACT in B. pertussis 
pathogenesis is highlighted in both murine and human studies.  
Tracheal cytotoxin (TCT) 
 TCT is not currently used in aP vaccines and is not unique to B. pertussis. TCT is a 
disaccharide-tetrapeptide monomer of peptidoglycan that is present in all Gram-
negative bacteria (61). ACT is released as part of normal bacterial cell growth as they 
remodel their cell wall. Due to the lack of the cytoplasmic membrane protein called 
AmpG, which normally participates in recycling of the peptidoglycan fragment, TCT is 
constitutively released into the environment and is not under control of the BvgAS two-
component system controlling other virulence factor gene expression. Because TCT is 
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released from the bacteria it acts locally on cells of the respiratory system to promote B. 
pertussis infection. TCT acts directly on nonciliated respiratory cells to induce IL-1𝛼, 
leading to increased nitric oxide (NO) synthase activity and subsequent NO production 
(62-63). TCT’s ability to induce NO production is dependent on LPS (62). The NO is then 
able to diffuse to neighboring ciliated epithelial cells further promoting respiratory tract 
inflammation.     
Filamentous hemagglutinin (FHA) 
 FHA is one of the most important adhesions and like PT, is included in all of the 
current aP vaccines. FHA has binding domains specific for heparin sulfate, carbohydrate, 
and integrin binding via an Arg-Gly-Asp site (64). Due to the multiple binding sites, FHA 
mediates initial adhesion to ciliated epithelial cells of the upper respiratory tract. 
Dissemination of B. pertussis down to the lower respiratory tract is mediated by FHA. 
Secretion of FHA to the cell wall has been shown to be dependent on an outer 
membrane accessory protein named FhaC as FhaC is able to make channels within the 
outer membrane (65). In addition to its binding characteristics, FHA is also an immune 
modulator. In mice, FHA primarily acts an immune suppressor. Systemic administration 
of FHA suppressed pro-inflammatory cytokine and enhanced anti-inflammatory cytokine 
release from innate cells, in addition to generating regulatory T cells and reduced colitis 
induced intestinal inflammation (66). Infection studies in B. bronchiseptica further 
clarified FHA’s immunosuppressive role (67-68). Interestingly, the role of FHA in a 
human context appears to be inflammatory rather than anti-inflammatory. FHA elicited 
pro-inflammatory cytokine release from human innate and epithelial cells (69-70).    
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Fimbriae (FIM) 
 FIM is a surface exposed structure that has heparin binding activity. The major 
subunits of FIM, FIM2 and FIM3, are serotype specific and have been shown to be 
serologically distinct (71). FIM antigens have been included as antigens in current aP 
vaccines; however not to the same extent that PT and FHA have been. FIM were shown 
to important for colonizing the respiratory tract in B. bronchiseptica infections (72).  
Pertactin (PRN) 
 PRN is an auto transporter protein that mediates B. pertussis adhesion to 
eukaryotic cells via its Arg-Gly-Asp binding site; however, PRN also contains proline-rich 
regions and leucine-rich repeats (73). PRN contributes to B. pertussis pathogenesis by 
resisting neutrophil-mediated clearance (74). PRN antigens are commonly used in 
current aP vaccines. Because PRN is highly polymorphic, the circulating B. pertussis 
strains may have different PRN variants that are included in aP vaccines. In addition, 
PRN-negative strains are beginning to emerge across the globe. The first reported PRN-
negative strain was in 2012 in France (75), with many other PRN-negative reports 
following (76-77). PRN appears to be dispensable to the bacteria as PRN-negative strains 
can evade aP generated immunity better than PRN-positive strains (78). The emergence 
of PRN-negative B. pertussis strains highlights the need for newly developed protective 
antigens in next-generation aP vaccines.      
Type III secretion (T3S) system 
 In comparison to other Gram-negative bacteria (i.e. Yersinia spp.), the T3S 
system of B. pertussis is not well characterized. Four B. pertussis proteins: Bsp22, BopN, 
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BopD, and BteA have been shown to be secreted. The structure and function of the B. 
pertussis is similar to other Gram-negative bacteria. This is a syringe-like structure that 
extends from the surface of the bacteria and facilitates direct translocation of effector 
molecules into host cells. The first reports of the contribution the T3S system plays 
during infection came from studies in B. bronchiseptica. These studies reveled that B. 
bronchiseptica uses T3S to persist within the murine respiratory tract (79). The ability of 
B. bronchiseptica to persist during infection is likely due to the ability of the T3S system 
to modulate innate immunity. Re-stimulated splenocytes from T3S mutant B. 
bronchiseptica produced more IFN-𝛾 and less of the immunosuppressive cytokine IL-10, 
suggesting that T3S down regulates host immunity (80). In addition, the T3S system 
from B. bronchiseptica has been shown to be important for modulating DC maturation 
(81-82). The first evidence of a functionally active T3S system in B. pertussis was 
reported in 2008 (83). Mutation of the effector molecule bscN, which abolished protein 
secretion, resulted in a reduced ability to colonize the respiratory tract of mice (83). 
Reduced colonization was the result of an increase in innate pro-inflammatory cytokine 
release in the lungs, elevated antigen specific IFN-𝛾 and IL-17, as well as increased 
antibody responses (83). These results confirm an immunosuppressive role of the T3S 
system in B. pertussis infections and provides evidence of the importance of T3S during 
B. bronchiseptica and B. pertussis infections. Another interesting finding from the work 
of Fennelly et al., (83) was that a number of laboratory-adapted strains of B. pertussis 
did not secrete the effector molecule Bsp22. This reversibility of T3S system expression 
was confirmed by Gaillard et al., (84). In addition to finding that laboratory-adapted 
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strains did not have a functional T3S system in vitro, they reported that the T3S system 
can become functional in vivo when the bacteria are put into a host; this was also true in 
the laboratory-adapted strains as well (84).     
Host immune responses to B. pertussis infection 
 Our understanding of what protective immunity looks like comes from a large 
body of work examining the host immune response to B. pertussis infection. The first 
line of defense against B. pertussis infections occurs at the upper respiratory tract and 
involves cells of the innate immune system. These lung resident cells include airway 
mucosal dendritic cells (AMDCs) and alveolar macrophages (AMs). The innate immune 
system helps to control early infection, and polarizes the adaptive immune response 
necessary to clear the infection. AMDCs will take up antigen at the site of infection and 
migrate to the lymph nodes to prime an adaptive immune response (85-86). On the 
other hand, AMs residing at the site of infection uptake and kill B. pertussis directly (87). 
These resident cells respond to, and become activated by, the many PAMPs expressed 
by B. pertussis. Many of the virulence factors have been shown to stimulate PRRs of the 
innate immune system. These resident cells within the lung not only act as the first line 
of defense, they also orchestrate further immune responses that prime the adaptive 
immune response and facilitate the recruitment of other immune cells.  
 In addition to AMDCs and AMs, several other cell types contribute to B. pertussis 
clearance, especially during the early stages of infection. 𝛾𝛿 T cells, have been shown to 
be important in the early immune response. 𝛾𝛿 T cells release an early source of IL-17 
which promotes cell trafficking into the lungs as well as antimicrobial peptide 
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production (88-89). IL-17 release in combination with the cytokine CXCL2 (MIP-2) 
secreted from macrophages and epithelial cells promotes neutrophil influx to the site of 
infection. Neutrophils have been shown to be an important cell type for controlling B. 
pertussis infections by antibody-mediated phagocytosis, intracellular killing of B. 
pertussis, and the production of neutrophil extracellular traps (81-82). Natural killer (NK) 
cells have also been shown to play an important role in early innate immune control of 
B. pertussis infection. NK cells primarily exert their protective effects through the 
release of IFN-𝛾. IFN-𝛾 activates macrophages and depletion of NK cells from mice 
infected with B. pertussis reduced IFN-𝛾 release resulting in bacterial dissemination 
from the respiratory tract to the liver (83). While these innate cells play a critical role in 
the early stages of infection, a polarized adaptive immune response is critical in 
controlling late stages of infection, primarily by augmenting neutrophil and macrophage 
bactericidal activity.  
 CD4+ T cells have been shown to play an important role in B. pertussis clearance 
as adaptive transfer of B. pertussis specific CD4+ T cells, but not B. pertussis specific CD8+ 
T cells into immunosuppressed mice resulted in effective bacterial clearance (84). CD4+ 
T cells mediate their immune activation through cytokine release. Th1 and Th17 CD4+ T 
cells release IFN-𝛾 and IL-17, respectively. The role of Th1 and Th17 cells in protective 
immunity against B. pertussis was investigated in IFN-𝛾-/-  and IL-17-/- mice which 
demonstrated a reduced ability to clear B. pertussis from the lungs (85-86). Moreover, in 
the case of the IL-17-/- mice, the inability to clear the pathogen was associated with a 
reduction in neutrophils within the lungs during infection (86). Once polarized by 
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AMDCs in the lymph nodes, primed T cells proliferate and differentiate into Th1 and 
Th17 cells. These cells then migrate back to the site of infection, and enhance 
macrophage and neutrophil bactericidal activity through IFN-𝛾 and IL-17 production, 
respectively.  
Pertussis Epidemiology 
Global burden and economic impact  
 For the past few decades, the use of either the whole cell B. pertussis vaccine 
(wP) or the currently aP vaccine has significantly reduced the global burden of the 
disease, although pertussis still remains endemic in both developed and developing 
countries. In addition, B. pertussis is undergoing a reemergence in many parts of the 
world. Estimates of the global burden of B. pertussis has been complicated by a number 
of issues from inadequate and/or underreporting, constant changes in surveillance and 
diagnostic protocols, as well as routine modifications to vaccine schedules as well as 
vaccine components (87). While the global incidence of pertussis is tricky, more recent 
statistics show that in a 2010 analysis, there were 16 million reported B. pertussis cases 
worldwide, with 195,000 deaths (88). A separate report completed in 2013 determined 
there were an estimated 136,000 cases worldwide that year (89). Given the great 
difficult in accurately reporting B. pertussis cases, underreporting is a significant 
concern. Specifically, in the United States there have been a number of reported B. 
pertussis outbreaks. Minnesota experienced a pertussis outbreak resulting in 4,144 
reported cases (90). In the same year, there were a total of 4,918 cases in Washington 
State (91). During the same time period and into 2014, pertussis was widespread 
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throughout California. In 2014, 10,831 cases were reported, the highest number in any 
one year (92). In terms of the economic impact of pertussis, often times costs can be 
high due to hospitalization. Total societal costs due to pertussis was estimated to be 
approximately $800 for adolescents and $1,950 for adults per case (93). Clearly 
pertussis is still active globally and negatively impacts human health worldwide.  
Clinical presentation 
 Clinical progression of a B. pertussis infection is identified by 3 common stages: 
1. Catarrhal 2. Paroxysmal 3. Convalescent. Each stage can vary in length, but typically 
can last 1-3 weeks, with complete recovery taking much longer. The course and duration 
of the disease is dependent on age of patient, vaccination history, infectious agent (i.e. 
B. pertussis versus B. parapertussis), and infectious dose. The three stages are most 
likely noticed and identified in infants and young children, while adolescents and adults 
usually present with milder symptoms and may go undiagnosed. The incubation period 
for B. pertussis is around 7-10 days. In the first stage, symptoms are often overlooked 
because they are similar to other viral infections (94). Interestingly, in the catarrhal 
stage, the bacterial burden is extremely high and the individual is most contagious at 
this stage. In the second stage, the paroxysmal stage, patients experience severe 
coughing bouts as well as the characteristic inspiratory whooping sound. Presently, it is 
not clear if one of the many toxins or virulence factors are responsible for the coughing. 
In the final stage, convalescence, coughing bouts are less in frequency and are not as 
severe.   
B. pertussis vaccines 
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 To date, there have been 2 available vaccines for B. pertussis: the wP vaccine as 
well as the aP vaccine. The wP vaccine was first introduced in the United States in the 
late 1940s. the wP vaccine consisted of inactivated B. pertussis and has been given in 
combination with diphtheria and tetanus toxoids. The cases of B. pertussis in the United 
States plummeted to approximately 1,000 in 1976 after the implementation of the wP 
vaccine (95).  Despite its effectiveness, the wP vaccine fell out of favor due to safety 
concerns of reported local and systemic reactions (96-97). In rare cases, serve 
neurological diseases such as encephalopathy, spasms, and sudden infant death 
syndrome were reported (96,98-99) The antigenicity and subsequent adverse reactions 
can likely be attributed to LPS and other innate stimulating agents on the bacterial 
surface. The continued adverse reactions from the wP vaccine prompted the 
development of less reactogenic vaccines consisting of purified antigens from B. 
pertussis. These vaccines, or derivations of these vaccines, are currently used today and 
are classified as aP vaccines. The first aP vaccine was developed in Japan in 1984 (100). 
Interestingly, the composition of the current aP vaccines are not uniform in the number 
and/or amount of antigens. Mutant PT and FHA are the only two antigens included in 
every aP vaccine. Others include PRN or fimbrial proteins. These new aP vaccines are 
given with diphtheria and tetanus toxoids and absorbed in alum as an adjuvant. Many 
different aP vaccines have undergone rigorous safety and toxicity testing and have been 
deemed safe and immunogenic. Edwards et al., (101-102) concluded that all 13 aP 
vaccines tested were found to be safer and produced less severe adverse reactions and 
were at least as immunogenic as compared to wP vaccines.   
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Reemergence of B. pertussis  
 The reemergence of pertussis related diseases is a complex issue and is most 
likely the result of a combination of multiple factors. First, many circulating B. pertussis 
strains have undergone pathogen adaptation and genetic changes, especially in aP 
vaccine antigens (103-105). One explanation for this is vaccine induced selective 
pressure (106-107). Two of the major antigens that have undergone genetic changes are 
PRN and PT. PRN-negative strains have been identified in many different parts of the 
world (77,108-110). In the United States, more than 50% of the collected strains were 
PRN-negative in 2012 (108). Interestingly, PRN-negative strains appeared to have a 
competitive advantage over PRN-positive strains in mixed infections in mice (78). In 
addition, PRN protein variants found in circulating B. pertussis strains are not included in 
the vaccine strain. PRN2 and PRN3 protein variants have been found to outperform 
PRN1 by enhanced colonization and increased transmissibility (111). In the case of PT, 
strains with genetic changes within the PT promoter produce slightly more PT than 
previously circulating strains (112), and are circulating globally. Given that vaccine 
selection pressure is accelerating at an increased pace with the aP vaccines, and that 
current antigens included in the aP vaccine are no longer present on many isolates, the 
need for new vaccination strategies will be important moving forward. 
 Second, recent research indicates that the current aP vaccines fail to induce 
protective immunity and vaccine induced immunity may wane overtime. The data from 
both mouse and human studies indicate that CD4+ Th1 and to a lesser extent CD4+ Th17 
cells are critical for protective immunity generated by vaccination. In animal studies, wP 
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vaccination conferred protective adaptive immunity mediated by Th1 and Th17 cells, 
while aP vaccination promoted non-protective Th2 type responses (84,86, 113). Th2 
type responses have been shown to redundant in animal models (86). Human studies 
also highlight suboptimal immunity induced by aP vaccines. An analysis of T cell 
responses in children reveal that aP vaccination promotes Th2 type responses, while wP 
vaccination induces strong Th1 immune responses (114-115). In addition to suboptimal 
immunity induced by aP vaccines, the longevity of protective immunity has been shown 
to wane over time. In head to head comparisons of long term cellular immunity induced 
by aP or wP vaccination in children, Schure et al., (116) found that aP vaccination 
actually produced stronger B. pertussis specific CD4+ T cell responses compared to wP 
vaccinated children. However, analysis of vaccine induced responses 5 years after 
primary pertussis vaccination levels of IL-17 production from aP vaccinated PBMCs was 
reduced compared to wP primed children (117). In addition, aP vaccination lead to 
significantly more end-stage differentiated CD4+ T cells responses compared to wP 
vaccination, suggesting the memory capacity of the immune responses is reduced in the 
aP vaccinated children (117). Together, these reports highlight a major inadequacy with 
the aP vaccine, potentially contributing to the increased incidence of pertussis cases in 
many countries.     
Finally, one of the hurdles pertussis researchers have had to overcome is that 
many of the animal models currently used to understand pertussis pathogenesis and 
vaccine induced immunity are not natural hosts to B. pertussis. For example, mice and 
other small mammals do not exhibit the classical whooping cough symptom. Recently, a 
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baboon model has been developed and has greatly enhanced our understanding of B. 
pertussis infection and transmission. One of the most striking finding from baboon 
studies is that while aP vaccination prevented clinical symptoms of B. pertussis, the 
baboons were highly colonized and were able to infect naïve baboons (113). This finding 
is significant in that in aP vaccinated areas, while clinical identification of whooping 
cough may be low, there may be a significant portion of the population that are 
colonized and able to transmit B. pertussis to susceptible newborns and infants who 
have not yet received aP vaccination. In addition, aP vaccination in the baboon model 
induced a mixed Th1/Th2 response and failed to prevent colonization while wP 
vaccination provided protection and induced a mixed Th1/Th17 response (113), 
confirming the importance of both Th1 and Th17 cells in protective immunity against B. 
pertussis.  
Approaches to improve aP vaccines 
Due to the number of shortcomings of current aP vaccines, the need for better 
vaccines has been recognized by a number of authorities in the field. Although a number 
of approaches have been suggested, a large amount of work has centered around 
developing new protective antigens or adjuvants that when added to current aP 
vaccines will skew vaccine induced immunity toward Th1/Th17 type responses. It is 
thought that the numerous PAMPs included in the wP vaccine are what contributed to 
long term protective immunity. These PAMPs activate the innate immune system and 
promote inflammatory cytokine release and DC maturation to induce Th1/Th17 cellular 
immunity (118). Current aP vaccines are absorbed in alum and it has been suggested 
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that there are no classical PAMPs included in the aP vaccines. Although PT has been 
shown to have immune stimulating properties, vaccine preparation strategies have 
destroyed PT’s immune stimulating ability (119). To that end, replacement or 
supplementation with innate stimulating adjuvants is one strategy to enhance aP 
vaccine immunogenicity and efficacy.  
A TLR2 agonist of B. pertussis when combined with the components of the aP 
vaccine enhanced protection from an aerosol B. pertussis challenge, induced robust 
IgG2a antibodies, and enhanced IL-17 and IFNy production from antigen stimulated 
splenocytes ex vivo compared with the aP vaccine in alum (120). A TLR4 agonist, 
monophosphoryl lipid A (MPL), when mixed with the aP vaccine increased protection 
against B. pertussis challenge when compared with the aP vaccine in alum adjuvant, 
while suppressing Th2 responses (121). A separate TLR agonist, LpxL1 (122), a 
genetically engineered LPS from Neisseria meningitidis, enhanced antigen specific IFNy 
and IL-17 CD4+ T cells and increased the number of specific memory CD4+ TCM cells when 
added to the aP vaccine (123). Finally, CpG oligonucleotides from bacterial DNA that 
activate TLR9 have been shown to induce antigen-specific IgG2a titers (124) and Th1 and 
Th17 cells (125) when added to the aP vaccine (86). These studies show the feasibility 
and effectiveness of incorporating novel TLR agonists into the aP vaccine to enhance 
pertussis specific immunity that will not only promote the proper adaptive immune 
responses, but could also augment the long-term efficacy of the aP vaccine.  
The importance of stimulating the innate immune system during vaccination and 
the subsequent generation of protective immunity is highlighted by the efficacy of the 
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live-attenuated B. pertussis vaccine BPZE1. This vaccine is designed for intranasal 
administration and has been genetically modified to remove or inactivate DNT, TCT, and 
PT mice (126). BPZE1 has been found to be safe in mice (126), and in humans during a 
Phase I clinical trial (127). Importantly, BPZE1 induced strong B. pertussis specific Th1 
responses and provided protection against B. pertussis in mice (128) as well as 
protected mice against B. parapertussis (129). The benefit of adding PAMPs to enhance 
protection either by the addition of TLR stimulating molecules to the aP vaccine or novel 
vaccines that seek to harness innate immune stimulation to promote protective cellular 
responses opens the door to more efficient approaches to significantly decrease 
pertussis cases globally.  
Rationale of current work 
 Based on the current literature, the strategy of adding TLR stimulating agents to 
the aP vaccine to skew aP induced immunity has proven successful. Recent work in our 
laboratory has identified a number of novel TLR ligands purified from the T3S system of 
many Gram-negative bacteria (130). These molecules have been shown to activate TLR2 
and TLR4, induce NF-𝜅B/AP-1 signaling, and promote inflammatory cytokine release in 
vitro (130-131). Interestingly, we have successfully demonstrated that the N-terminus 
from these proteins functions to modulate innate immune activation (131). This is 
unique in that not only have our proteins been shown to activate TLR2 and TLR4, but 
these proteins can be modified to enhance or reduce NF-𝜅B/AP-1 signaling. In addition 
to the immune stimulating properties of these proteins, we believe that given the 
extracellular location of the T3S system, BscF may also act as a protective antigen in B. 
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pertussis infections. YscF, a purified needle protein from Y. pestis, protected mice 
against a Yersinia pestis infection (132). In addition, a Chlamydia T3S system needle 
protein induced specific humoral and cellular responses, and decreased Chlamydia loads 
in mice (133). In the current study, we investigated the immune stimulating properties 
of a novel B. pertussis specific protein from the T3S system called BscF. Further, we 
assessed the ability of BscF to induce both humoral and cellular responses in mice 
necessary for vaccine induced protection, and characterized the contribution of BscF to 
a laboratory prepared aP vaccine. 
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CHAPTER II 
 
CHARACTERIZATION OF THE IMMUNE RESPONSE INDUCED BY BSCF, A PURIFIED TYPE 
III SECRETION SYSTEM NEEDLE PROTEIN FROM BORDETELLA PERTUSSIS 
 
Introduction 
 
Bordetella pertussis is a gram-negative bacterium and the causative agent of the 
vaccine preventable disease whooping cough (pertussis). With the development of a 
whole cell pertussis (wP) vaccine in the 1940s-1950s, cases of pertussis were 
dramatically reduced. The wP vaccine proved to be too reactogenic and was replaced 
with a less reactogenic vaccine: the subunit acellular pertussis (aP) absorbed in alum as 
the adjuvant in the 1990s. Despite continued widespread vaccination, whooping cough 
has again reemerged as a global health threat not only in newborns and infants, but 
surprisingly among adults as well (88). This resurgence has been linked to antigenic 
variation in many circulating B. pertussis strains (103,134,135,76,136), defective long-
term immunological memory (137,138,139,140), and ineffective immune responses that 
are necessary for long-term protection (141,113). It has been demonstrated in both 
mice and humans that the aP vaccine induces robust Th2 responses, with a limited Th17 
response (114,142,117,143). The aP vaccine has been shown to prevent clinical pertussis 
symptoms, but does not prevent bacterial colonization or transmission (113).  
On the other hand, the wP vaccine has been shown to promote Th1 and Th17 
responses and protective immunity in both mice and humans (114,144,86). 
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Effectiveness of the wP vaccine has been largely attributed to its many antigens 
and pathogen associated molecular patterns (PAMPs) that bind and activate innate 
pattern recognition receptors (PRRs) (27). Given the contribution of the many PAMPs to 
the effectiveness of the wP vaccine, we propose that the addition of PRR stimulating 
agents could enhance the effectiveness of the current aP vaccine.  
Endogenous B. pertussis specific PAMPs activate the innate immune system 
through PRRs – including Toll-like receptors (TLRs), promote inflammatory cytokine 
release, and direct pertussis-specific adaptive immunity (118). Because PAMPs appear 
to be an important aspect of the wP vaccine, it has been suggested that the addition of 
TLR agonists to the aP vaccine could re-direct the immune response generated by the aP 
vaccine to a more wP-like immune response. A TLR2 agonist (lipoprotein BP1569 and its 
synthetic derivative, LP1569) of B. pertussis when combined with the components of the 
aP vaccine induced strong Th1 and Th17 responses and enhanced protection from an 
aerosol B. pertussis challenge (120). A TLR4 agonist, monophosphoryl lipid A (MPL), 
increased protection against B. pertussis challenge while suppressing Th2 responses 
(121). In addition, other TLR4 agonists have been shown to enhance immunity 
generated by the aP vaccine (123). Finally, CpG oligonucleotides from bacterial DNA that 
activate TLR9 have been shown to enhance aP-directed pertussis immunity. 
(86,124,125). These studies demonstrate the feasibility and effectiveness of 
incorporating novel TLR agonists into the aP vaccine to enhance pertussis specific 
immunity.  
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We have recently identified that the needle proteins from bacterial type III 
secretion (T3S) systems are novel TLR agonists (130,131]. Interestingly, these proteins 
activate TLR2 and TLR4, promote pro-inflammatory cytokine release, and can be 
modified to modulate TLR signaling (130,131). Immunization with T3S needle and 
translocon proteins have shown to produce protective immunity in mice against a 
number of gram-negative pathogens (145,132,146,147,148,149). In the current study, 
the immune stimulating properties of BscF, a purified T3S apparatus protein from B. 
pertussis, were examined. In addition, the ability of BscF to provide protective immunity 
against a sub-lethal B. pertussis challenge was also assessed. We demonstrate that BscF 
induces NF-kB and/or AP-1 signaling following TLR2 or TLR4 ligation. This activation 
promotes strong inflammatory cytokine release from both mouse and human innate 
cells. Furthermore, mice immunized with BscF produce robust BscF specific humoral and 
adaptive immune responses; contributing to modest protection against a sub lethal B. 
pertussis challenge. Our findings demonstrate that BscF from B. pertussis is a TLR 
agonist, like other T3S needle proteins, that could contribute to a next-generation 
pertussis vaccine through its innate immune stimulating properties or by acting as a 
protective antigen. 
Materials and Methods 
 
Bacterial strains and growth conditions 
 E. coli Novablue (EMDMIllipore, Billerica MA), BL21 (DE3) star (Invitrogen, 
Carlsbad, CA), LPS modified BL21 (DE3) (161), TOP10 (Invitrogen), and Bordetella 
pertussis (Tohama I, ATCC BAA-589) were stored at -80°C in 25% glycerol (vol/vol). E. coli 
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strains were grown at 37°C in LB broth (BD, Franklin Lakes, NJ) or on tryptose blood agar 
base (TBA, BD) plates, with kanamycin (50 µg/ml) as needed. B. pertussis was 
maintained as previously described (162). Briefly, B. pertussis was grown at 37°C on 
Bordet-Gengou (BG) solid medium (RemelTM Thermo Fisher Scientific, Lenexa, KS) 
supplemented with glycerol and 15% sterile sheep’s blood (Lampire Biological Labs, 
Pipersville, PA). B. pertussis liquid cultures were grown in Stainer-Scholte broth 
supplemented with heptakis (2,6-di-O-methyl-ß-cyclodextrin; Sigma-Aldrich, St. Louis, 
MO) and Stainer-Scholte supplements at 37°C. In the case of the GFP-expressing 
pertussis, both solid and broth medium were supplemented with kanamycin (50 µg/ml) 
and gentamicin (30 µg/ml).    
Expression and purification of His-tagged recombinant proteins 
 Template DNA for amplification was generated by using a DNeasy kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. Oligonucleotide primers 
(Eurofins MWG Operon, Inc. Huntsville, AL) were used to amplify BscF DNA from B. 
pertussis Tohama I strain: BscF forward (5’-CAC CAT GGC CAT TAA CCT GGG AGG-3’) and 
BscF reverse (5’-TCA ACT CGC CTT CTG TAT GAC GCC C-3’). PCR was performed using Pfu 
Ultra polymerase (Agilent Technologies, Santa Clara, CA). The amplified DNA was cloned 
in frame with a N-terminal His-tag into pET200 by using a Champion TOPO expression kit 
(Invitrogen). Plasmid for protein expression was purified from E. coli TOP10 with a 
Qiaprep Miniprep kit (Qiagen). Purified plasmid DNA was then transformed into 
chemically competent E. coli BL21 (DE3) Star (Invitrogen). Plasmid constructs were 
verified by sequencing (Eurofins MWG Operon, Inc.).  
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 Protein purification was performed as previously described (130,131). Briefly, E. 
coli BL21 (DE3) Star (Invitrogen) was grown overnight at 37°C in a shaking water bath in 
non-inducing medium (50X M, 1 M MgSO4, 40% glucose, 5% aspartic acid (163)) 
supplemented with antibiotic. Bacteria were then inoculated into auto-inducing medium 
(50X M, 1 M MgSO4, 50X 5052, NZ-amine S, yeast extract, distilled water (163)) 
supplemented with antibiotic and grown to an A620 of 0.6 to 0.8. Cells were harvested by 
centrifugation at 4,000 x g for 10 min at 4°C and resuspended with wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10% glycerol (wt/vol)). The bacterial suspension was then 
French pressed at 20,000 lb/in2 twice to lyse cells. The lysate was centrifuged at 10,000 
x g for 20 min at 4°C. The supernatant was collected and diluted with 1,000 ml of wash 
buffer before application to a pre-equilibrated TALON metal affinity resin (Clontech, 
Mountain View, CA) column. The lysate was applied to the column twice followed by 
washing the column with 15 bed volumes of wash buffer. Bound protein was eluted in 
elution buffer (50 mM NaH2PO4, 200 mM NaCl,150 mM imidazole, and 20% glycerol 
(wt/vol)). Purified protein was concentrated by centrifugation (Amicon Ultra centrifugal 
filters, Millipore, Billerica, MA), and dialyzed against phosphate-buffered saline (PBS) 
plus 10% glycerol (wt/vol) in Slide-A-Lyzer dialysis cassettes (Pierce, Thermo Fisher 
Scientific, Rockford, IL). Protein concentration was determined by Bradford protein 
assay (Pierce, Thermo Fisher Scientific), and purified protein was stored at -80°C for 
future use. Purified BscF was shown to be > 95% pure by coomassie blue staining of 15% 
SDS-PAGE gels as previously described (130,131,132).   
Stimulation of SEAP reporter cell lines 
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THP1-XBlue cells (InvivoGen, San Diego, CA) were maintained in RPMI 1640 
(Gibco, Thermo Fisher Scientific) supplemented with 10% heat inactivated fetal bovine 
serum ((FBS); Atlanta Biologicals)), 25 mM HEPES, 2 mM L-glutamine, 1 mM sodium 
pyruvate, and 50 µg/ml Pen-Strep at 37°C with 5% CO2. HEK-Blue cells (InvivoGen) were 
maintained in DMEM (Gibco, Thermo Fisher Scientific) supplemented with 10% heat 
inactivated FBS, 2 mM L-gluatmine, 100 µg/ml Normocin (InvivoGen), HEK-Blue 
selection (InvivoGen), and 50 µg/ml Pen-Strep at 37°C with 5% CO2. These cells contain 
the secreted embryonic alkaline phosphatase (SEAP) reporter gene under the control of 
NF-kB and AP-1. THP-1XBlue cells and HEK-Blue cells were seeded at 3 X 106 cells/ml and 
2.5 X 105 cells/ml into 96-well plates, respectively. Cells were suspended in infection 
medium as described by the manufacturer. Proteins were added to a final concentration 
of 1 µg/ml. Cells were stimulated at 37°C with 5% CO2 for 24 h. Quantification of SEAP 
from the supernatant was detected using Quanti-Blue reagent (InvivoGen) according to 
the manufacturer’s protocol. SEAP activity was quantified by measuring the absorbance 
at 630 nm using a microplate reader (Synergy HT, BioTek, Winooski, VT) and was 
analyzed with KC4 v3.3 software (BioTek).  
Quality control for contamination of purified BscF protein 
 Quality control of purified proteins was performed as previously described (130). 
Needle proteins and flagellin (Salmonella Typhimurium, InvivoGen) were incubated with 
40 µg/ml of proteinase K at 37°C for 16 h to ensure activity from purified proteins was 
from protein. Proteinase K was inactivated with 1.6 mg/ml of phenylmethylsulfonyl 
fluoride (PMSF, Sigma-Aldrich). To check for lipopolysaccharide (LPS) contamination, 
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THP-1XBlue cells were pretreated with 20 µg/ml of polymyxin B (InvivoGen). Following 
enzymatic digestion or polymyxin B treatment, the THP-1XBlue cells were stimulated as 
indicated above. BscF was also expressed as indicated above in E. coli strains lacking LPS 
to further rule out LPS contamination. These protein preparations were compared 
directly to BscF expressed in E. coli BL21 (DE3) Star (Invitrogen) by measuring SEAP 
activity from THP-1XBlue cells.  
Cell line growth and bone marrow derived cell isolation and differentiation 
 THP-1 cells (ATCC TIB-202) were maintained in RPMI 1640 (Gibco, Thermo Fisher 
Scientific) containing 10% heat inactivated FBS, 50 mM 2-mercaptoethanol, and 50 
µg/ml Pen-Strep at 37°C with 5% CO2. Mouse macrophage-like RAW 264.7 (ATCC TB-71) 
cells were maintained in DMEM (Gibco, Thermo Fisher Scientific) supplemented with 
10% heat inactivated FBS at 37°C with 5% CO2. Bone marrow cells were collected from 
femurs of the following C57BL/6 mice: WT, Toll-like receptor 2 (TLR2), and TLR4 
Knockout, Asc-/-, Nlrp3-/-, Nlrc4-/-, Caspase11-/-, Caspase1-/- (Caspase11Tg), and Caspase1-/-
Caspase11-/-. Femurs were aseptically removed from each hind leg, briefly soaked in 
70% ethanol, and placed in fresh RPMI medium (10% heat inactivated FBS, 2 mM L-
glutamine, 50 mM 2-mercaptoethanol, and 50 µg/ml Pen-Strep). Both ends of the femur 
were cut and the bone was flushed with 10 ml of RPMI and the cells were collected in a 
50 ml conical tube. The cell suspension was centrifuged at 400 x g for 10 min at 4°C. The 
cells were resuspended in RPMI supplemented with 40 ng/ml granulocyte-macrophage 
colony-stimulating factor (GMCSF; PeproTech, Rocky Hill, NJ), seeded at a density of 4 X 
106 in 20 ml of medium in a 150 x 20 mm round culture dish, and incubated at 37°C with 
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5% CO2. On day 3, the cells were supplemented with 20 ml of fresh RPMI + 40 ng/ml 
GMCSF and incubated for an additional 3 days. At day 6, the non-adherent cells 
dendritic cells (DCs), and the adherent bone marrow derived macrophages (BMDM) 
were used for subsequent analysis.  
Innate cytokine analysis 
 THP-1 cells and mouse RAW 264.7 cells were seeded in triplicate at 1 X 106 
cells/ml into 24-well plates and stimulated with 1 µg/ml of needle protein for 24 h at 
37°C with 5% CO2. PBS, 1 µg/ml LPS (E. coli K12; InvivoGen), and/or 1 µg/ml Pam3CSK4 
(InvivoGen) were used as negative and positive controls. BMDM were seeded in 
triplicate at 5 X 105 cells/ml into 24 well plates and stimulated with indicated 
concentrations of needle protein for 24 h at 37°C with 5% CO2. Following stimulation, 
cells were centrifuged at 400 x g for 5 min at 4°C and the cellular supernatant was 
removed and stored at -20°C for future analysis. Numerous human and mouse innate 
cytokines were measured by DuoSet enzyme-linked immunosorbent assay (ELISA) kits 
from R&D Systems (Minneapolis, MN) or mouse inflammation panel cytometric bead 
analysis (CBA) kit (BioLegend, San Diego, CA). CBA samples were measured by flow 
cytometery (LSR II, Becton Dickinson, San Jose, CA), and analyzed with software 
provided by the manufacturer (LEGENDplex v7.0).     
Phagocytosis inhibition and identification of intracellular pro-IL-1𝜷 
 To prevent phagocytosis, mouse DCs were seeded and pretreated with 0.25 
𝜇g/ml cytochalasin D (Sigma) for 1 h prior to stimulation with 10 𝜇g/ml BscF. Following 
24 h stimulation, cell culture supernatant was collected and levels of secreted IL-1𝛽 was 
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measured via ELISA. Intracellular pro-IL-1𝛽 was measured in stimulated DCs by flow 
cytometry. Cells were collected, permeabilized, and stained with anti-pro-IL-1𝛽 PE 
conjugagted (Biolegend). Within the single cell population, MFI of PE was calculated as a 
measure of intracellular pro-IL-1𝛽. 
Mouse immunization and intranasal challenge 
 6-8 week old C57BL/6 male mice were immunized intra peritoneally with 40 µg 
of purified BscF in either PBS, or diluted 1:1 with aluminum hydroxide gel (Alhydrogel 
adjuvant 2%, InvivoGen). Mice were boosted with 20 µg of BscF at 2 and 4 weeks post 
vaccination. Mice that received PBS injections served as controls. Two weeks after the 
last immunization, mice were intra nasally challenged with 2 X 106 CFU of B. pertussis 
Tohama I in a 25 µl inoculum. 7 d post infection, lungs were aseptically removed, and 
homogenized (Bullet blender, Next Advance, Averill Park, NY) in 1 ml of sterile PBS. Lung 
homogenate was centrifuged at 130 x g for 1 min at 4°C, serial dilutions were plated on 
15% blood BG plates, and incubated at 37°C for 4 d. Lung bacterial burden was 
determined by counting CFUs. All animal experiments were approved by the IACUC at 
the University of North Dakota. 
ELISA assay of antibody levels in mouse serum 
 ELISA plates (Costar EIA/RIA, Corning) were coated with 100 µl of 1 µg/ml BscF 
diluted in PBS and incubated overnight at 4°C. Plates were washed with wash buffer (1X 
PBS, 0.05% Tween-20), and blocked with blocking buffer (1X PBS, 1% BSA, 0.05% Tween-
20) and incubated at room temperature for 1 h. Plates were again washed and 
incubated with serially diluted mouse serum for 1 h at room temperature. Following 
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incubation, plates were washed, blocked for 10 min at room temperature with blocking 
buffer, and incubated with rabbit anti-mouse IgG biotinylated (Invitrogen) antibody 
diluted 1:10,000 in blocking buffer for 1 h at room temperature. Both wash and blocking 
steps were repeated as indicated above, and plates were incubated with streptavidin-
HRP (Invitrogen) diluted 1:2,000 in blocking buffer for 1 h at room temperature. For 
measuring IgG isotypes, isotype specific goat anti-mouse IgG1, IgG2a, IgG2b, IgG2c, 
IgG3, IgM, and IgA (Sigma-Aldrich) diluted 1:1,000 in blocking buffer was incubated 
following serially diluted serum for 30 min at room temperature. Plates were washed 
and blocked as indicated above, and bound IgG was detected with biotinylated rabbit 
anti-goat IgG (Sigma-Aldrich) for 30 min at room temperature. Plates were again washed 
and blocked, and incubated with streptavidin-HRP (Invitrogen) diluted 1:2,000 in 
blocking buffer for 30 min at room temperature. Plates were washed with wash buffer 
and incubated with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate for 10 min at room 
temperature. The reaction was stopped by adding 50 µl of 1 M H2SO4. Optical densities 
(OD) were measured at 450 nm with a microplate reader (Synergy HT, BioTek) and were 
analyzed with KC4 v3.3 software (BioTek). End point titer was determined as the last 
dilution that gave an OD 2 times above the pre-immune serum. 
Analysis of cellular response elicited by needle protein vaccination 
 At 2 weeks post last immunization, spleens were collected from mice receiving 
either PBS, BscF, or BscF diluted in alum, and processed to a single cell suspension. 
Splenocytes were suspended in RPMI (10% heat inactivated FBS and 50 µg/ml of Pen-
Strep) and seeded at 1 X 106 cells/ml into 24 well plates. Splenocytes were stimulated 
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with 1 µg/ml BscF or medium alone for 72 h at 37°C with 5% CO2. Plates were 
centrifuged at 400 x g for 5 min at 4°C and cellular supernatant was removed. IFN-y, IL-
17A, and IL-4 production was determined by DuoSet ELISA kits (R&D Systems). 
Opsonophagocytosis assay 
 B. pertussis Tohama I was electroporated with plasmid pCW504 (provided by Dr. 
Allison Weiss, Univ of Cincinnati) generating a GFP-expressing B. pertussis strain. These 
bacteria were opsonized with 6-week mouse serum from BscF-immunized mice or with 
pre-immune serum as a negative control for 30 min at 37°C. Opsonized bacteria were 
incubated on a RAW 264.7 cell monolayer seeded in 24 well plates at a multiplicity of 
infection (MOI) of 50 for 30 min at 37°C to allow for binding and internalization. Prior to 
incubation, the plates were centrifuged at 800 x g for 5 min to facilitate cell contact. 
Non-attached bacteria were removed by washing the cell monolayer 5 times with pre-
warmed PBS. Cells were scraped from the plate, Fc receptors were blocked, and 
incubated with 0.25 µg anti-CD11b antibody-PB conjugated (Biolegend) diluted in FACS 
buffer (1X PBS, 2% heat inactivated FBS) for 30 min at room temperature. Cells were 
washed with FACS buffer, and resuspended in FACS buffer. Single stained controls were 
used to facilitate analysis. Samples were collected by flow cytometery (BD LSR II) and 
data were analyzed with FlowJo (FlowJo LLC, Ashland, OR). Phagocytosis was estimated 
by mean fluorescence intensity (MFI).  
Statistical analysis 
 Data were assembled into graphs using GraphPad Prism, version 5.0f (GraphPad 
Software, La Jolla, CA). Data were analyzed using one-way analysis of variance (ANOVA) 
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followed by Bonferroni’s multiple comparison test. Differences were considered 
statistically significant when p<0.05.  
Results 
 
Protein in purified protein preparations is responsible for NF-𝜿B/AP-1 activation in 
THP-1XBlue cells 
To examine contamination in the BscF protein preparations, we first examined 
possible lipopolysaccharide (LPS) contamination. Pre-treating cells with polymyxin B 
significantly reduced LPS activation down to background levels (Fig 1A). Polymyxin B 
treatment of purified BscF resulted in a slight decrease in NF-𝜅B and/or AP-1 activation 
in THP-1XBlue cells (Fig 1A). Although polymyxin B treatment resulted in a slight 
decrease in SEAP activation by BscF, the level of NF-𝜅B and/or AP-1 activation was still 
significantly higher than LPS treated with polymyxin B (Fig 1A). Due to the slight 
decrease in NF-𝜅B and/or AP-1 activation of BscF when pre-treated with polymyxin B, 
we expressed BscF in an LPS free E. coli strain. THP-1XBlue cells were stimulated with 
BscF expressed in BL21 (DE3) or LPS free E. coli BL21 (DE3) and NF-𝜅B and/or AP-1 
activation was measured 24 hours later. There was no difference in NF-𝜅B and/or AP-1 
activation between the two BscF protein preparations (Fig 1B); confirming LPS is not a 
significant contaminant in our purified T3S system needle protein preparations. This is 
consistent with our previous work demonstrating no LPS contamination in our protein 
preparations by Limulus Amebocyte Lysate (LAL) assay, as well as purifying LcrG in the 
same manner as BscF in the current study, and demonstrating no activation of NF-𝜅B 
and/or AP-1 when THP-1XBlue cells were treated with purified LcrG (130,131). 
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To further demonstrate that protein in purified needle preparations is 
responsible for NF-𝜅B and/or AP-1 activation in THP-1XBlue cells, BscF or flagellin (TLR5 
agonist used as positive control) were incubated with the serine protease, Proteinase K, 
for 16 h at 37°C prior to stimulation. As anticipated, Proteinase K treatment reduced NF-
𝜅B and/or AP-1 activation by flagellin to background levels (Fig 1C). Proteinase K-treated 
needle proteins also failed to induce NF-𝜅B and/or AP-1 activation (Fig 1C), confirming 
that protein caused the cellular response seen in the THP1-XBlue and HEK-Blue cells. 
Together, these results demonstrate that BscF protein is responsible for inducing SEAP 
activity by THP-1Xblue and HEK-Blue cells. 
Purified BscF activates NF- 𝜿B/AP-1 signaling through TLR2 and TLR4 
 T3S system needle proteins from Yersinia pestis (YscF) and a number of other 
gram-negative pathogens act as pathogen associated molecular patterns (PAMPs) and 
activate Toll-like receptors 2 (TLR2) and 4 (TLR4) (130,131). Bordetella pertussis relies on 
a T3S system for virulence (83) and expresses a T3S needle protein (BscF) that shares 
low sequence similarity to YscF (23% identity). These observations led us to examine if 
BscF acts similarly to other needle proteins by inducing downstream signaling of TLR 
activation. Evaluation of TLR signaling was assessed using human THP-1XBlue and HEK-
Blue cells engineered with a secreted embryonic alkaline phosphatase (SEAP) reporter 
system. SEAP expression is under control of the transcriptional activators NF- 𝜅B and AP-
1; which are critical transcriptions factors for innate immune responses. An increase in 
SEAP expression is indicative of increased TLR signaling through NF-𝜅B and/or AP-1. 
Treating THP-1XBlue cells with 1 µg/ml BscF significantly induced NF-𝜅B and/or AP-1 
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activation (Fig 2A) compared to the untreated controls. To confirm the TLRs that BscF is 
stimulating through, HEK-Blue cells transfected with either hTLR2 or hTLR4 were 
stimulated with 1 µg/ml of BscF and SEAP expression was measured 24 h after 
stimulation. BscF stimulation induced NF-𝜅B and/or AP-1 activation in both HEK-Blue 
hTLR2 and hTLR4 cells (Figs 2B and C). These results demonstrate that BscF acts similarly 
to other characterized T3S system  needle proteins (130,131) by acting as a PAMP to 
activate NF-𝜅B and/or AP-1 signaling through TLR2 and TLR4 ligation. 
BscF induces inflammatory cytokines by innate immune cells 
 We demonstrated that BscF activates NF-𝜅B and/or AP-1 activation with SEAP as 
a reporter gene. We next examined the possibility that BscF could induce inflammatory 
cytokines from both murine and human innate immune cells. Murine Raw 264.7 cells 
were treated with BscF for 24 h and several prototypical innate cytokines were 
measured in the supernatant. As expected, low levels of cytokines were detected in 
non-treated cells. Stimulation with either LPS or Pam3CSK4 as positive controls induced 
significant TNF-𝛼, IL-6, and IL-1𝛽 production when compared to untreated levels (Figs 
3A-C). BscF also stimulated TNF-𝛼, IL-6, and IL-1𝛽 production by murine Raw 264.7 cells 
(Figs 3A-C). Because the reporter cell lines used are human cell lines, we confirmed that 
BscF could promote inflammatory cytokine release from non-transfected human THP-1 
cells. BscF, in addition to other known TLR ligands, induced strong IL-12p40, TNF- 𝛼, and 
IL-1𝛽 production by human THP-1 cells (Figs 3D-F). These findings demonstrate that in 
addition to inducing TLR signaling, BscF activated both murine and human innate 
immune responses in vitro.  
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BscF induction of proinflammatory cytokines is largely dependent on TLR4 signaling 
 We have shown that BscF induces NF-𝜅B and/or AP-1 signaling downstream of 
TLR2 and TLR4 activation, and subsequent inflammatory cytokine release from murine 
and human innate cells. We next demonstrated that BscF more strongly activates TLR4 
by using TLR2 and TLR4 knockout bone-marrow derived macrophage (BMDM) cells from 
mice. BscF induced significantly less TNF- 𝛼, IL-6, and IL-12p40 in the TLR4 knockout 
BMDM cells when compared to wild type cells (Fig 4). Inflammatory cytokine release 
was also significantly lower in the TLR4 knockout cells when compared to TLR2 knockout 
cells. TLR2 knockout cells also resulted in a marked reduction in IL-6, and IL-12p40 
production, although the reduction was not as great when compared to the TLR4 
knockout cells (Fig 4). These findings demonstrate that although BscF induces NF-𝜅B 
and/or AP-1 signaling through both TLR2 and TLR4 in the human SEAP reporter cell line, 
BscF-induced inflammatory cytokine release from mouse BMDM cells is largely 
dependent on TLR4 activation.   
BscF induced IL-1𝜷 through an NLRP3 Caspase 1 dependent mechanism requiring 
phagocytosis 
Having shown that BscF promotes IL-1𝛽, among other inflammatory cytokines, 
by human THP-1 and mouse RAW 264.7 cells, BscF must also engage a cytosolic pattern 
recognition receptor (PRR) of the nucleotide-binding domain leucine rich repeat (NLR) 
family in addition to TLR signaling. It has been shown that T3S system components and 
bacterial flagellin are detected by the intracellular NLRC4 inflammasome 
(153,154,155,156,157). Using inflammasome deficient BMDMs and DCs, we 
demonstrated that BscF promotes IL-1𝛽 in an NLRP3 caspase-1 dependent mechanism 
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(Fig 5A and B). We confirmed that there was no defect in NF-𝜅B signaling as levels of 
TNF-𝛼 were similar in all cell types, with a slight increase in the Caspase1-/- (Caspase11Tg) 
cells (Fig 5C). We next investigated the role of phagocytosis in BscF induced IL-1𝛽 
production. Blocking phagocytosis by cytochalasin D pretreatment significantly reduced 
IL-1𝛽 release from stimulated DCs (Fig 6A). Inhibition of IL-1𝛽 production was coupled 
with an increase in intracellular pro-IL-1𝛽 (Fig 6B and C). These data suggest that while 
normal NF-𝜅B signaling occurred, resulting in accumulating pro-IL-1𝛽, internalization of 
BscF is required to activate the NLRP3 inflammasome to cleave pro-IL-1𝛽 into mature IL-
1𝛽. Together, these results demonstrate that BscF induces IL-1𝛽 by engaging the NLRP3 
inflammasome upon internalization, in addition to its TLR activating properties.  
Characterization of BscF serum from immunized mice 
 To examine the immune response generated by BscF immunization, total BscF-
specific IgG and antibody isotyping was performed in the serum from mice vaccinated 
with BscF alone or BscF absorbed in aluminum hydroxide (alum). Immunization with 
purified BscF induced significant BscF-specific antibody responses (Fig 7A). The presence 
of alum enhanced the antibody response to BscF immunization (Fig 7A). Surprisingly, 
BscF immunization alone produced robust IgG1 and IgG2b responses, with modest 
IgG2c, IgG3, IgA, and IgM responses (Fig 7B); while BscF absorbed in alum produced 
higher titers to many IgG isotypes (Fig 7B). Given the extracellular location of BscF 
within the T3S, we assessed the ability of BscF-specific IgG to opsonize and enhance 
phagocytosis of GFP-expressing B. pertussis. Interestingly, serum from BscF immunized 
mice significantly enhanced bacterial uptake by Raw 264.7 cells compared to non-
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immunized mouse serum (Fig 7C). These findings demonstrate that BscF immunization 
promotes the induction of a mixed Th1, Th17 response, evidenced by the IgG2 response 
and a Th2, Th17 response, demonstrated by the IgG1 response.  Additionally, 
immunization produced BscF-specific antibodies that enhanced B. pertussis opsonization 
and phagocytosis. 
BscF vaccination indirectly promotes Th1 and Th17 immune responses in mice 
 It is clear that protective immunity against B. pertussis is mediated by Th1 cells 
and Th17 cells (114,144,86). We have shown that BscF promotes inflammatory cytokine 
production by innate cells, specifically IL-12, IL-1𝛽, and IL-6, which are associated with 
differentiation of Th1 and Th17 cells. We next characterized the adaptive immune 
response to BscF immunization. Spleens from mice immunized with either BscF alone or 
BscF absorbed in aluminum hydroxide gel were harvested 6 weeks post first vaccination, 
processed to a single cell suspension, and stimulated with BscF for 3 days. Stimulation of 
splenocytes with BscF induced strong production of IFN-𝛾 as measured by ELISA (Fig 8A). 
In addition, BscF stimulation induced IL-17A production (Fig 8B). BscF stimulation failed 
to elicit production of the Th2 cytokine IL-4 (Fig 8C). These findings indicate that BscF 
immunization indirectly promotes IFN- 𝛾 and IL-17A production by T cells in vitro, 
suggesting BscF may either provide protective immunity by acting as a protective 
antigen in vivo, or could augment innate and adaptive immunity generated by an 
acellular vaccine.  
BscF vaccination reduces lung bacterial burden in a sub lethal infection with B. 
pertussis 
 38 
 Having shown that BscF stimulates innate cytokine release, produces robust 
antibody responses in vivo, and drives strong Th1 and Th17 T cell responses, we next 
characterized the ability of BscF to act as a protective antigen in vivo. Following 
vaccination with BscF alone or BscF absorbed in aluminum hydroxide gel mice were 
challenged with 2 X 106 CFU of B. pertussis Tohama I in a 25 µl inoculum intranasally. 
Lungs were aseptically removed, homogenized in PBS, and serial dilutions of lung 
homogenate were plated on 15% blood BG plates. BscF absorbed in alum promoted a 
modest, but significant, reduction in bacterial colonization of the lungs 7 d post infection 
when compared to mock immunized mice (Fig 9). Immunization with BscF alone did not 
significantly reduce lung bacterial burden when compared to mock immunized mice (Fig 
9). These data demonstrate that BscF can act as a protective antigen in a sub lethal B. 
pertussis infection model, possibly by the induction of Th1 and Th17 cells. Although the 
protective immunity generated by BscF immunization per se was very modest in our 
infection model, we provide persuasive evidence that BscF could be an ideal candidate 
to include in an acellular pertussis vaccine. 
Discussion 
 
Type III secretion (T3S) system needle proteins are pathogen-associated 
molecular patterns (PAMPs) that act as toll like receptor 2 (TLR2) and toll like receptor 4 
(TLR4) ligands to induce innate inflammatory cytokine release in a MyD88-depedendent 
mechanism (130,131). In this study, we characterized the immunostimulatory properties 
of the T3S needle protein from B. pertussis, called BscF. It has been shown that TLR4 
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signaling is critical for generating protective cellular immunity by pertussis vaccination 
or natural infection (150,151).  
Additionally, the efficacy of the whole cell pertussis (wP) vaccine is attributed to 
its numerous PAMPs that activate pattern recognition receptors (PRR) (27). These 
studies clearly highlight the important contribution PAMPs play in developing protective 
immunity against pertussis. The role of PAMPs in augmenting pertussis-specific cellular 
immunity is further highlighted by a number of studies using the current acellular 
pertussis (aP) vaccine (86,120,121,123,124,125). In the current study, we demonstrated 
that BscF, like other gram-negative needle proteins, is a strong PAMP leading to 
activation of NF-𝜅B and/or AP-1 signaling through TLR2 and TLR4 (Fig 2). Additionally, 
BscF stimulation of innate cells induced strong inflammatory cytokines that promoted 
protective adaptive immunity against B. pertussis.   
 Recently, it has been established that host immunity to B. pertussis involves 
cellular immunity, specifically Th1 and Th17 cells (114,143,86,141). The development of 
cellular immunity is influenced by activation of the innate immune system. Antigen 
presenting cells (APCs) that become activated through PAMP recognition, release 
polarizing cytokines IL-12, IL-6, and IL-1β, which dictate the differentiation of Th1 and 
Th17 cells. Our data demonstrates that BscF stimulation of murine and human innate 
cells induced robust IL-12, IL-6, and IL-1𝛽 production, indicating the ability of BscF to 
induce Th1 and Th17 polarizing cytokines (Figs 3 and 4).  Interestingly, the ability of BscF 
to induce these inflammatory cytokines appeared to be largely dependent upon TLR4 
activation in mice, although the loss of TLR2 did result in decreased cytokine production 
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from murine BMDM cells (Fig 4). We believe that the ability of BscF to engage multiple 
PRRs is unique and noteworthy because many of the other PAMPs used in combination 
with the aP vaccine engage only a single TLR (e.g. TLR2, TLR4, or TLR9). In addition, the 
ability of BscF to activate both murine and human cells suggests that BscF could be 
included in an improved B. pertussis human aP vaccine. 
 Th17 cells have been shown to be important in immunity to B. pertussis (141). B. 
pertussis specific Th17 cellular protective immunity and effective bacterial clearance 
were shown to be dependent on stimulation of the NLRP3 inflammasome by adenylate 
cyclase toxin, and subsequent IL-1𝛽 release (60). Interestingly, BscF stimulation resulted 
in the production of IL-1𝛽 from murine and human innate cells (Fig 3). To investigate 
which inflammasome BscF signals through, inflammasome deficient BMDMs and DCs 
were stimulated with BscF. BscF induced the production of IL-1𝛽 in an NLRP3 and 
caspase-1 dependent mechanism through the adaptor molecule ASC (apoptosis-
associated speck-like protein containing a caspase recruitment domain) (Fig. 5). 
Additionally, inhibition of phagocytosis by cytochalasin D significantly reduced secreted 
IL-1𝛽 while levels of intracellular pro-IL-1𝛽 increased (Fig 6). These data suggest that 
BscF is a potent agonist for two unique receptors: TLRs and the NLRP3 inflammasome. 
We believe that BscF induces NF-𝜅B/AP-1 signaling downstream of TLRs leading to the 
production of pro-IL-1𝛽 as well as other inflammatory cytokines. Internalization of BscF, 
and activation of the NLRP3 inflammasome then activates caspase-1 to cleave pro-IL-1𝛽 
into mature IL-1𝛽 (Fig 10).  This finding is in contrast to other reports that demonstrate 
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T3S system components and bacterial flagellin interact with the NLRC4 inflammasome 
(153,154,155,156,157).  
The previous studies (153,154,155,156,157) differ significantly in a number of 
ways from the current study in terms of how the T3S system components or flagellin 
were administered to the innate cells in vitro: 1. recombinant flagellin was fused to the 
amino-terminal domain of anthrax lethal factor to target the protein to the cytosol 
through an endocytosis mediated pathway (156) 2. the T3SS rod protein PrgJ and the 
needle protein PrgI from Salmonella typhimurium were transfected directly into 
macrophages following lipopolysaccharide (LPS) stimulation (155) 3. Cells were treated 
with bacteria expressing intact T3S system to directly inject effector molecules into the 
cytosol (157). In the current study, BscF was added to the culture medium, not directly 
into the cell cytoplasm. It is possible that the differences in methodology among the 
studies contributes to the discrepancies in inflammasome activation. In support of that 
conclusion, bacterial amyloids produced in Escherichia coli and Salmonella typhimurium 
produce IL-1𝛽 in vitro when administered in the culture medium of BMDM cells through 
cooperation of TLR2 and the NLRP3 inflammasome (152). In addition to the Th1 
polarizing cytokines produced by BscF stimulation, the ability of BscF to activate 
intracellular inflammasomes and produce IL-1𝛽 suggests that BscF may provide B. 
pertussis specific cellular immunity through Th17 cells.    
In the current study we confirmed that BscF vaccination induced robust antibody 
responses in mice (Figs 7A and B). Interestingly, BscF immunized serum effectively 
opsonized B. pertussis compared to non-immunized serum (Fig 7C). One of the 
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insufficiencies of the aP vaccine is its inability to generate bactericidal antibodies 
(158,159,160). Due to the extracellular localization of BscF on B. pertussis, we anticipate 
that BscF might be a protective antigen, in part through the humoral response elicited 
by BscF. It has been demonstrated that T3S system needle and translocon proteins act 
as protective antigens, presumably through the generation of a robust antibody 
response (145,132,146,147,148,149). Presently, it is unclear how BscF antibodies might 
provide protection in vivo. We are currently addressing the ability of BscF-specific 
antibodies to enhance complement mediated bacterial killing, inhibit bacterial 
adherence, or augment opsonophagocytosis and subsequent bacterial uptake and 
killing.   
 Despite widespread vaccination, whooping cough still remains as a global health 
threat (88). This is due, in part, to the aP vaccine promoting robust Th2 responses 
(114,142,117,143). Although the aP vaccine can control pertussis related symptoms, it 
may not prevent bacterial colonization or transmission (113). An improved pertussis 
vaccine should elicit strong Th1 responses, in addition to Th17 responses. Here, we 
demonstrated that BscF immunization indirectly enhanced IFN𝛾 and IL-17A production 
in splenocytes from immunized mice (Fig 8). In addition, immunization with BscF 
absorbed in aluminum hydroxide gel provided modest protection in a sub lethal B. 
pertussis challenge (Fig 9). Although bacterial burden is still relatively high, these results 
demonstrate that BscF acts as a protective antigen; in addition to its innate stimulating 
properties.  Modest protection is also seen with YscF-induced protection against 
Yersinia pestis (132).  Taken together, these data demonstrate that BscF has the 
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immunomodulatory properties to be a beneficial vaccine candidate in an improved aP B. 
pertussis vaccine. BscF acts as a strong innate agonist, induces robust inflammatory 
cytokine release, and promotes protective cellular immunity critical to clear a B. 
pertussis infection. BscF immunization produced robust humoral responses, and acted 
as a modest protective antigen in a sub lethal B. pertussis infection. Studies are currently 
ongoing to investigate the contribution of BscF when added to the aP vaccine. 
Considering the shortcomings of the aP vaccine, BscF has significant potential to 
enhance a next generation subunit pertussis vaccine. 
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Figure 1. Characterization of BscF protein preparation. (A) BscF or LPS were treated 
with polymyxin B (PMB, 20 µg/ml) before addition to THP1-XBlue cells. (B) THP-1XBlue 
cells were treated with 1 µg/ml of BscF expressed in BL21 (DE3) or BscF expressed in an 
LPS free E. coli and activation of NF- 𝜅B and AP-1 was measured after 24 hours. (C) BscF 
and Flagellin (FLA) were treated with proteinase K (40 µg/ml). Following treatment with 
polymyxin B or proteinase K, THP-1XBlue cells were stimulated and NF- 𝜅B and AP-1 
activation was measured by SEAP detection after 24 hours. Data are representative of 
three experiments. ** Indicates p is between 0.01 and 0.001; *** Indicates p is between 
0.001 and 0.0001. 
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Figure 2. BscF activates NF-𝜿B/AP-1 signaling in THP1-XBlue and HEK293 cells in a TLR2 
and TLR4 dependent mechanism. (A) THP-1XBlue reporter cells were treated PBS, 1 
µg/ml of BscF, or 1 µg/ml of LPS dissolved in PBS. (B) HEK-Blue hTLR2 and (C) HEK-Blue 
hTLR4 reporter cells were treated with PBS, 1 µg/ml of BscF, 1 µg/ml of HKLM (Heat 
Killed Listeria monocytogenes; TLR2 agonist), or 1 µg/ml of LPS (TLR4 agonist) dissolved 
in PBS. SEAP levels were measured as an indirect measure of NF-𝜅B/AP-1 activation. 
Data are presented as mean ± standard error of triplicate wells. Data are representative 
of at least three experiments. **** Indicates p < 0.0001.  
 
 
 
 46 
 
 
 
Figure 3. BscF stimulation induces robust inflammatory cytokine release from murine 
and human innate cells. Murine Raw 264.7 cells were treated with 1 µg/ml of BscF, 1 
µg/ml of LPS, 1 µg/ml of Pam3CSK4, or medium. After 24 h stimulation, levels of (A) TNF-
𝛼, (B) IL-6, and (C) IL-1𝛽 release were measured in the supernatant by ELISA. Human 
THP-1 cells were treated with 1 µg/ml of BscF, 1 µg/ml of LPS, or 1 µg/ml of Pam3CSK4 
for 24 h. Release of (D) IL-12p40, (E) TNF-𝛼, and (F) IL-1𝛽 was measured in the 
supernatant by ELISA after 24 h stimulation. Data are presented as mean ± standard 
error of triplicate wells. Data are representative of three experiments. * Indicates p is 
between 0.05 and 0.01; *** Indicates p is between 0.001 and 0.0001; **** Indicates p < 
0.0001.  
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Figure 4. BscF induction of inflammatory cytokines is largely dependent upon TLR4 
activation. Wild type, TLR2, and TLR4 knockout murine bone marrow cells were 
differentiated in the presence of GM-CSF and stimulated with 1 µg/ml of BscF, 1 µg/ml 
of LPS, or medium for 24 h. Release of (A) TNF-𝛼, (B) IL-6, and (C) IL-12p40 was 
measured in the supernatant by ELISA after 24 h stimulation. Data are presented as 
mean ± standard error of triplicate wells. Data are representative of three experiments. 
** Indicates p is between 0.01 and 0.001; *** Indicates p is between 0.001 and 0.0001.   
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Figure 5. BscF stimulates IL-1𝜷 release in an Nlrp3 caspase-1 dependent mechanism. 
Inflammasome component KO (A) BMDMs and (B) DCs were treated with 10 µg/mL of 
BscF and incubated for 24 hours at 37 ℃ with 5% CO2. Following incubation, cell culture 
supernatant was collected and levels of IL-1𝛽 and (C) TNF-𝛼 were measured by ELISA. 
Data are presented as mean ± SE of triplicate wells. ** Indicates p is between 0.05 and 
0.001. *** Indicates p is between 0.001 and 0.0001. **** Indicates p is < 0.0001.  
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Figure 6. Pre-treatment with cytochalasin D disrupts IL-1𝜷 release and results in an 
increased accumulation of cytosolic pro-IL-1𝜷. DCs were treated with 0.25 µg/mL of 
cytochalasin D for 1 hour at 37 ℃ prior to stimulation with 10 µg/mL of BscF for 24 
hours at 37 ℃ with 5% CO2. Following incubation, cell culture supernatant was collected 
and level of (A) IL-1𝛽 was measured by ELISA. Cells were collected, permeabilized, 
stained with anti-pro-IL-1𝛽, and analyzed by flow cytometry. (B) pro-IL-1𝛽 and (C) mean 
fluorescence intensity were measured. Data are presented as mean ± SE of triplicate 
wells. * Indicates p is between 0.05 and 0.01; **** Indicates p is < 0.0001.  
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Figure 7. BscF immunization induces a robust humoral response and B. pertussis 
opsonizing antibodies. Mice were immunized with 40 µg/ml of BscF diluted in PBS or 
absorbed in aluminum hydroxide gel at day 0 followed by boost immunizations at 2 and 
4 weeks with 20 µg/ml of BscF. Serum samples (n = 4-5) were collected at 6 weeks and 
(A) BscF-specific IgG titer and (B) IgG isotype titer were determined by ELISA. Pre-
immunization serum samples were collected as control. GFP-expressing B. pertussis 
were opsonized with BscF immunized serum or naïve serum as control incubated with 
murine Raw 264.7 cells. Non-opsonized bacteria were used to determine background 
GFP mean fluorescence intensity. (C) GFP geometric mean fluorescence intensity was 
measured in CD11b+ macrophages. Each dot represents a different serum sample. 
Antibody data presented as mean ± standard error. Antibody data are representative of 
two experiments. * Indicates p is between 0.05 and 0.01. 
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Figure 8. BscF enhances activation of Th1 and Th17 cells, but not Th2 cells. Spleen cells 
from BscF immunized mice were processed to a single cell suspension and stimulated 
with 1 µg/ml of BscF (black bars) or medium (open bars) for 3 days. Supernatants were 
tested for (A) IFN-𝛾, (B) IL-17A, and (C) IL-4 by ELISA. Data presented as mean ± standard 
error; n = 4 mice/group. Data are representative of at least two experiments. * Indicates 
p is between 0.05 and 0.01; *** Indicates p is between 0.001 and 0.0001. 
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Figure 9. BscF vaccination acts as a protective antigen against B. pertussis. Mice were 
immunized with 40 µg/ml of BscF diluted in PBS or absorbed in aluminum hydroxide gel 
at day 0 followed by booster immunizations at 2 and 4 weeks with 20 µg/ml of BscF. 
Two weeks after the last immunization, mice were challenged with an intranasal 
inoculum of 2x106 CFU. (A) CFU counts were performed on lung homogenates 7 days 
post infection. Data presented as mean ± standard error; n = 4-5 mice/group. Data are 
representative of two experiments. ** Indicates p is between 0.01 and 0.001. 
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Figure 10. Proposed model of T3S system needle protein-induced IL-1𝜷 secretion. BscF 
stimulates TLR4 receptor complex leading to activation of NF-𝜅B and expression of pro-
inflammatory cytokines, including pro-IL-1𝛽. We believe the BscF-TLR complex is 
internalized via actin rearrangement leading to endocytosis of BscF. BscF then can 
activate Nlrp3 and caspase-1 cleaving pro-IL-1𝛽 to IL-1𝛽, which is then secreted into the 
extracellular space. 
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CHAPTER III 
 
PURIFIED TYPE III SECRETION SYSTEM NEEDLE PROTEINS INDUCE CLATHRIN-
DEPENDENT NF-𝜿B/AP-1 SIGNALING FROM ENDOSOMAL COMPARTMENTS 
 
Introduction 
 
 The type III secretion (T3S) system is a protein secretion system that is conserved 
among many gram-negative bacteria used to deliver virulence factors into eukaryotic 
host cells to exploit the host by manipulating intracellular signaling (164,165,166,79). A 
key component of the T3S system is a needle-like structure that extends from the 
surface of the bacteria. This hollow structure is formed by the polymerization of single 
proteins: YscF in Yersinia spp., PrgI and SsaG (Salmonella pathogenicity island 1 and 
Salmonella pathogenicity island 2, respectively), PscF in Pseudomonas spp., MxiH in 
Shigella flexneri, and BscF in Bordetella spp. 
(166,167,168,169,170,171,172,173,174,175,176). Given the cellular localization of the 
T3S system needle complex, this structure has the potential to interact with the innate 
immune system.   
 During host-pathogen interactions, the innate immune system is the first to 
respond to invading pathogens by recognizing conserved pathogen associated molecular 
patterns (PAMPs). Toll-like receptors (TLRs) are a family of receptors that become 
activated by microbial products to modulate innate and adaptive immune responses 
(177). The cellular localization of these receptors either at the plasma membrane or 
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within intracellular endosomal compartments allows immune surveillance of both 
extracellular and intracellular pathogens (178). Endocytosis of plasma membrane TLRs 
has been shown to amplify ligand-induced TLR signaling from endosomal compartments 
as well as activate distinct intracellular signaling pathways (179,180,181).  One of the 
key players in TLR activation, endocytosis, and ligand specificity is CD14. CD14 is a GPI-
linked or soluble protein expressed on many TLR4 expressing cells and was first 
identified as a pattern recognition receptor (PRR) that binds directly to 
lipopolysaccharide (LPS) (182). CD14 has also been implicated in TLR4 endocytosis upon 
LPS stimulation (183). In addition to TLR4, CD14 has been shown to associate with TLR2 
to enhance ligand specificity (184,185,186) and endosomal-dependent NF-𝜅B signaling 
(187). The first TLR signaling event leading to early NF-𝜅B activation occurs at the 
plasma membrane through the adaptor proteins MyD88/TIRAP leading to the up 
regulation of inflammatory genes such as TNF-𝛼. A second signaling event occurs from 
the endosomal compartment through the adaptor proteins TRAM/TRIF leading to late 
NF-𝜅B signaling and type I interferon (IFN) production (188,189,190,191,192).         
Recently, T3S system needle proteins have been identified as TLR2 and TLR4 
ligands that induce NF-𝜅B/AP-1 activation and secretion of inflammatory cytokines in a 
MyD88-dependent manner (130). In addition, we identified that the N terminus of T3S 
system needle proteins is important for modulating TLR activation (131). Given the 
importance of endosomal TLR signaling we hypothesized that T3S system needle 
proteins may also exploit endosomal NF-𝜅B signaling to augment inflammatory cytokine 
release. In this study, we examined the mechanism leading to T3S system needle 
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protein-induced NF-𝜅B/AP-1 activation downstream of TLR2 and TLR4 in human HEK 
cells and monocytes. T3S system needle proteins: BscF, B. pertussis specific T3S system 
needle protein, and YscF, Y. pestis specific T3S system needle protein, were found to 
activate NF-𝜅B/AP-1 signaling from endosomal compartments mediated by a 
clathrin/dynamin dependent endocytosis as clathrin-dependent endocytosis inhibition 
significantly reduced NF-𝜅B/AP-1 signaling and inflammatory cytokine release. In 
addition, NF-𝜅B/AP-1 activation by T3S system needle proteins downstream of both 
TLR2 and TLR4 is mediated by CD14.  
Materials and Methods 
 
Bacterial strains and growth conditions 
 Escherichia coli Novablue (EMDMIllipore, Billerica MA), BL21 (DE3) star 
(Invitrogen, Carlsbad, CA), and TOP10 (Invitrogen) were stored at -80°C in 25% glycerol 
(vol/vol). E. coli strains were grown at 37°C in LB broth (BD, Franklin Lakes, NJ) or on 
tryptose blood agar base (TBA, BD) plates, with kanamycin (50 µg/ml) as needed.  
Expression and purification of His-tagged recombinant proteins 
 Template DNA for amplification was generated by using a DNeasy kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. Oligonucleotide primers 
(Eurofins MWG Operon, Inc. Huntsville, AL) were used to amplify BscF DNA from B. 
pertussis Tohama I strain: BscF forward (5’-CAC CAT GGC CAT TAA CCT GGG AGG-3’) and 
BscF reverse (5’-TCA ACT CGC CTT CTG TAT GAC GCC C-3’). Oligonucleotide primers 
(Eurofins MWG Operon, Inc. Huntsville, AL) were used to amplify YscF DNA from Y. 
pestis: YscF forward (5’- CGG GAT CCG ATG AGT AAC TTC TCT GGA TTT 3') and YscF 
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reverse (5’-CCG CTC GAG TGG GAA CTT CTG TAG GAT GCC-3’). PCR was performed using 
Pfu Ultra polymerase (Agilent Technologies, Santa Clara, CA). The BscF amplified DNA 
was cloned in frame with a N-terminal His-tag into pET200 by using a Champion TOPO 
expression kit (Invitrogen). The YscF amplified DNA was cloned in frame with a C-
terminal His-tag into pET24b (Novagen, Madison WI). Plasmids for protein expression 
were purified from E. coli TOP10 with a Qiaprep Miniprep kit (Qiagen). Purified plasmid 
DNA was then transformed into chemically competent E. coli BL21 (DE3) Star 
(Invitrogen). Plasmid constructs were verified by sequencing (Eurofins MWG Operon, 
Inc.).  
 Protein purification was performed as previously described (130,131). Briefly, E. 
coli BL21 (DE3) Star (Invitrogen) was grown overnight at 37°C in a shaking water bath in 
non-inducing medium (50X M, 1 M MgSO4, 40% glucose, 5% aspartic acid (163)) 
supplemented with antibiotic. Bacteria were then inoculated into auto-inducing medium 
(50X M, 1 M MgSO4, 50X 5052, NZ-amine S, yeast extract, distilled water (163)) 
supplemented with antibiotic and grown to an A620 of 0.6 to 0.8. Cells were harvested by 
centrifugation at 4,000 x g for 10 min at 4°C and resuspended with wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10% glycerol (wt/vol)). The bacterial suspension was then 
French pressed at 20,000 lb/in2 twice to lyse cells. The lysate was centrifuged at 10,000 
x g for 20 min at 4°C. The supernatant was collected and diluted with 1,000 ml of wash 
buffer before application to a pre-equilibrated TALON metal affinity resin (Clontech, 
Mountain View, CA) column. The lysate was applied to the column twice followed by 
washing the column with 15 bed volumes of wash buffer. Bound protein was eluted in 
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elution buffer (50 mM NaH2PO4, 200 mM NaCl,150 mM imidazole, and 20% glycerol 
(wt/vol)). Purified protein was concentrated by centrifugation (Amicon Ultra centrifugal 
filters, Millipore, Billerica, MA), and dialyzed against phosphate-buffered saline (PBS) 
plus 10% glycerol (wt/vol) in Slide-A-Lyzer dialysis cassettes (Pierce, Thermo Fisher 
Scientific, Rockford, IL). Protein concentration was determined by Bradford protein 
assay (Pierce, Thermo Fisher Scientific), and purified protein was stored at -80°C for 
future use.  
Human HEK and THP-1 cell stimulation 
HEK-Blue TLR2 and HEK-Blue TLR4 cells were suspended in DMEM and seeded at 
5x104 and 2.5x104 cells/well, respectively in 96 well plates. T3S system needle proteins 
were added to a final concentration of 1 μg/mL. 100 ng/ml of Pam3CSK4 (InvivoGen) 
and 1 ng/ml of LPS (E. coli K12; InvivoGen) were used as positive controls for HEK-Blue 
TLR2 and HEK-Blue TLR4 cells, respectively. Cells were stimulated at 37℃ in 5% CO2 for 
24h. For inhibition experiments, cells were pre-treated with Chlorpromazine (CPZ), 
Chloroquine (CHQ), Dynasore (Dyn), or blocking antibodies (10 𝜇g/ml; InvivoGen) for 1 
hour at 37℃ in 5% CO2 prior to stimulation. The plates were then centrifuged at 1,200 
rpm for 5 min at 4℃ and the supernatant was added to detection media and incubated 
37℃ in 5% CO2 for 2h. Quantification of SEAP, the secreted embryonic alkaline 
phosphatase reporter gene under the control of NF-κB and AP-1 in the HEK-Blue cells 
was used as a surrogate to measure TLR activation and was measured by reading the 
absorbance at 630 nm. THP-1 cells were suspended in RPMI and seeded at 1x106 
 59 
cells/well in 24 well plates and stimulated as indicated above. TNF-𝛼 was measured in 
the cell culture supernatant at 24 hours by ELISA.    
mRNA silencing 
 HEK-Blue TLR2 and HEK-Blue TLR4 cells were suspended in complete DMEM and 
seeded at 5x105 cells/well in 6 well plates or 1x105 cells/well in 12 well plates 1 day prior 
to transfection.  The following day, the cells were washed with PBS and treated with 1 
µM Accell siRNA against heavy chain clathrin 17 designed by supplier (GE Healthcare, 
Dharmacon™ Accell™ siRNA) or with 1 µM of non-targeting siRNA. After 24 h, complete 
DMEM was supplemented to the wells and transfection continued for a total of 72 h. 
The cells were re-seeded at 5x104 cells/well in 96 well plates and stimulated at 37℃ in 
5% CO2 for 24h. The plates were then centrifuged at 1,200 rpm for 5 min at 4℃ and the 
supernatant was added to detection media and incubated 37℃ in 5% CO2 for 2h. 
Quantification of SEAP was measured by reading the absorbance at 630 nm.     
Inhibitor cytotoxicity  
 HEK-Blue TLR2 and HEK-Blue TLR4 cells were treated with either Chlorpromazine 
(CPZ), Chloroquine (CHQ), Dynasore (Dyn) as indicated above and cell toxicity was 
measured by lactate dehydrogenase (LDH) release as indicated using the manufacturer’s 
instructions (ThermoFisher Scientific).     
Statistical analysis  
Data were assembled into graphs using GraphPad Prism, version 5.0f (GraphPad 
Software, La Jolla, CA). Data were analyzed using one-way analysis of variance (ANOVA) 
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followed by Bonferroni’s multiple comparison test. Differences were considered 
statistically significant when p<0.05. 
Results 
T3S system needle proteins induce NF-𝜿B/AP-1 downstream of TLR2 and TLR4 by 
clathrin-dependent endocytosis  
Recent data demonstrate the role of endosomal signaling downstream of TLR2 
and TLR4 to augment plasma membrane TLR signaling (179,180,181,187). Clathrin-
mediated signaling events, in addition to the GTPase dynamin, have shown to be crucial 
for localizing the TLR complex to the early endosome (180,187,193). Given the 
localization of TLRs within the endosomal compartments, and how endosomal signaling 
can augment NF-𝜅B activation and subsequent inflammatory cytokine production (187), 
we determined the role that endosomal TLR signaling plays in T3S system needle protein 
stimulated cells.  To determine the role of TLR internalization in the activation of NF-
𝜅B/AP-1 we utilized HEK-Blue TLR2 that express TLR2 and CD14, and HEK-Blue TLR4 cells 
which express TLR4, MD2, and CD14. These cells contain the secreted embryonic 
alkaline phosphatase (SEAP) reporter gene under the control of NF-κB and AP-1 in the 
HEK-Blue cells. HEK cells were treated with Chlorpromazine (CPZ), a clathrin-mediated 
endocytosis inhibitor, Chloroquine (CHQ), endosomal maturation inhibitor, and 
Dynasore (Dyn), the GTPase dynamin inhibitor, prior to T3S system needle protein 
stimulation. As shown in Figure 11, CPZ, CHQ, and Dyn significantly reduced NF-𝜅B/AP-1 
activation induced by both BscF and YscF in both HEK TLR2 as well as HEK TLR4 cells. 
These data suggest that TLR2 and TLR4 internalization is important to augment T3S 
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system needle protein-induced NF-𝜅B/AP-1 signaling. In addition, TLR internalization is 
mediated by clathrin and dynamin dependent mechanisms.   
Clathrin-mediated endocytosis mediates T3S system needle protein induced TNF-𝜶 
downstream of TLR2 and TLR4  
Because HEK cells are engineered cells that assess NF-𝜅B/AP-1 signaling by SEAP 
release, we wanted to examine the role of TLR endosomal signaling in a more realistic 
innate cell context. To that end, we treated human THP-1 cells with the CPZ, CHQ, and 
Dyn prior to T3S system needle protein stimulation and measured release of TNF-𝛼 in 
the cell culture supernatant. As indicated in Figure 12, CPZ, CHQ, and Dyn significantly 
reduced TNF-𝛼 release from T3S system needle protein stimulated THP-1 cells. These 
data demonstrate that clathrin-mediated endocytosis augments NF-𝜅B/AP-1 signaling 
and TNF-𝛼 expression downstream of TLR activation by T3S system needle proteins YscF 
and BscF.  
We further confirmed the role of clathrin in mediating NF-𝜅B/AP-1 signaling 
downstream of TLR2 and TLR4 in the HEK cells. Interestingly, gene silencing of the 
clathrin heavy chain in HEK TLR2 cells significantly reduced BscF induced NF-𝜅B/AP-1 
signaling, while the reduction of NF-𝜅B/AP-1 signaling in YscF stimulated cells did not 
reach significance (Fig 13A). Gene silencing of the clathrin heavy chain in HEK TLR4 cells 
did not significantly reduce NF-𝜅B/AP-1 signaling induced by BscF or YscF (Fig 13B). 
Brandt et al. demonstrated that targeting the clathrin heavy chain by gene silencing in 
HEK-BLUE TLR4 cells did not significantly reduce NF-𝜅B activation induced by LPS (187), 
and that the clathrin heavy chain was only partially inhibited by gene silencing. Our 
results suggest that T3S system needle proteins activate NF-𝜅B/AP-1 signaling 
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downstream of TLR2 and TLR4, which is augmented, in part, by clathrin-mediated 
endocytosis of the receptor complex.  
CD14 facilitates T3S system needle protein activation of NF-𝜿B/AP-1  
T3S system needle proteins from a number of gram-negative bacteria have been 
identified as TLR2 and TLR4 ligands that induce NF-𝜅B/AP-1 signaling and secretion of 
inflammatory cytokines in a MyD88-dependent manner (130,131). CD14 is a protein 
expressed on innate cells that has been shown to enhance ligand binding, increase 
ligand specificity, and facilitate endocytosis of TLR receptors (182,183,184,185,186,187). 
Using HEK-Blue TLR2 that express TLR2 and CD14, and HEK-Blue TLR4 that express TLR4, 
CD14, and MD2, we determined the contribution of CD14 to T3S system needle protein 
induction of NF-𝜅B/AP-1 signaling. CD14 blocking antibody significantly reduced NF-
𝜅B/AP-1 signaling induced by YscF and BscF in HEK-Blue TLR2 cells, while isotype control 
antibody had no affect (Fig 14A). For HEK-Blue TLR4 cells, blocking both CD14 and MD2 
significantly decreased NF-𝜅B/AP-1 signaling induced by YscF and BscF (Fig 14B). Isotype 
control antibody did not decrease signaling (Fig 4B). Neither CD14 or MD2 antibody 
alone significantly reduced NF-𝜅B/AP-1 signaling induced by YscF and BscF in HEK-Blue 
TLR4 cells (data not shown). These results suggest that CD14 enhanced T3S system 
needle protein induced NF-𝜅B/AP-1 signaling in HEK-Blue cells. 
LDH release from HEK-Blue cells treated with various pharmacological inhibitors  
 To ensure the reduction in NF-𝜅B/AP-1 signaling observed by pharmacological 
inhibition was not due to direct cell toxicity, HEK-Blue TLR2 and HEK-Blue TLR4 cells 
were pre-treated with either CPZ, CHQ, or Dyn, at the highest and lowest concentrations 
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and LDH was measured following treatment. To our surprise, CPZ significantly reduced 
cell viability in HEK-Blue TLR2 cells at both the highest and lowest concentrations (Fig 
15A). Lowest CPZ treatment did not reduce cell viability in the HEK-Blue TLR4 cells; 
however, the highest CPZ concentration contributed to cell toxicity (Fig 15B). Neither 
CHQ nor Dyn reduced cell viability at either the low or high concentrations (Fig 15). 
Despite the cytotoxic affect observed by CPZ, our results are in line with previously 
published data (187). Brandt et al., did not report any cytotoxic affects in human 
monocytes induced by CPZ at the same concentrations used in the current study (187). 
In addition, CPZ did not produce cytotoxic affects at the lowest concentration in HEK-
Blue TLR4 cells (Fig 15B), but still significantly reduced NF-𝜅B/AP-1 signaling (Fig 11A). 
These results suggest that the reduced NF-𝜅B/AP-1 signaling observed with 
pharmacological inhibition cannot solely be contributed to direct cytotoxic affects of the 
inhibitors.     
Discussion  
 The innate immune system is the first line of defense against invading 
pathogens. TLRs are a group of innate receptors that are distinguished by ligand 
specificity and cellular localization (178). The internalization of plasma membrane TLRs 
has been shown to be a mechanism to enhance plasma membrane signaling or initiate 
distinct signaling cascades originating from the endosomal compartments, despite 
initially thinking that this process was a way to attenuate TLR signaling (180,181,190). 
We have shown that T3S system needle proteins from many different gram-negative 
bacteria act as TLR2 and TLR4 ligands, induce My-D88 dependent NF-𝜅B/AP-1 signaling, 
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and promote inflammatory cytokine release (130,131); however, the contribution of 
endosomal NF-𝜅B/AP-1 signaling has not been addressed. In the current study, we 
demonstrate that T3S system needle proteins, YscF and BscF, activate NF-𝜅B/AP-1 
signaling from endosomal compartments. Our data indicate that clathrin-mediated 
endocytosis mediates NF-𝜅B/AP-1 activation, and that CD14 controls, in part, TLR 
activation.  
  Both TLR2 and TLR4 have been shown to be present within endosomal 
compartments (179,190,194,195). In the case of TLR4, early My-D88/TIRAP-dependent 
plasma membrane signaling leads to NF-𝜅B activation with a second endosomal-specific 
signaling event through TRAM/TRIF leading to late NF-𝜅B activation and IFN production 
(180,188,189,190,191,192). Like TLR4 signaling, endosomal-dependent signaling has 
been described by TLR2 as well (186,187,189). While plasma membrane signaling is a 
component in the generation of inflammatory cytokine production, data suggest that 
the contribution of endosomal signaling is primarily responsible for inflammatory 
cytokine production (180,196,197). Using our unique TLR ligands previously described to 
bind TLR2 and TLR4 (130,131), we demonstrate that these ligands also exploit 
clathrin/dynamin-mediated endosomal NF-𝜅B/AP-1 signaling to induce inflammatory 
cytokine release (Figs 11 and 12). Pharmacological inhibition of clathrin-mediated 
endocytosis with CPZ, endosomal maturation with CHQ, and dynamin with Dyn indicate 
endocytosis of T3S system needle proteins are necessary to augment NF-𝜅B/AP-1 
signaling. These data are consistent with reports demonstrating the requirement of 
internalization of TLR ligands to induce NF-𝜅B-controlled inflammatory cytokine release 
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and ligand recognition (187,198,199), and demonstrate that endosomal localization and 
TLR signaling augments T3S system needle protein-induced NF-𝜅B/AP-1 signaling and 
inflammatory cytokine release from human THP-1 cells.  
 In the current study, the pharmacological inhibitor CPZ significantly decreased 
HEK-Blue TLR2 and HEK-Blue TLR4 cell viability at the highest concentration used (Fig 
15). In addition, the lowest CPZ concentration also reduced cell viability in HEK-Blue 
TLR2 cells. This is surprising as it was reported by Brandt et al., (187) that no cell 
cytotoxicity in human monocytes was reported in their study using the same CPZ 
concentrations used in our study. No other cytotoxic affects were observed with any of 
the other inhibitors (Fig 15). Despite the direct cytotoxic effects of CPZ, specifically with 
the HEK-Blue TLR2 cells, CPZ reduced NF-𝜅B/AP-1 signaling in the HEK-Blue TLR4 cells in 
the absence of direct cytotoxic affects. Additionally, siRNA targeting the clathrin heavy 
chain in HEK-Blue TLR2 cells resulted in a significant inhibition of NF-𝜅B/AP-1 signaling 
induced by BscF (Fig 13A). Although YscF activation was reduced, it did not reach 
statistically significant levels (Fig 13A). No reduction in T3S system stimulated NF-𝜅B/AP-
1 signaling in HEK-Blue TLR4 cells treated with clathrin heavy chain siRNA was observed 
(Fig 13B). These results are consistent with Brandt et al., (187), and could also be 
attributed to only partial reduction in clathrin heavy chain expression by siRNA.  
 CD14 has been shown to be an important co-receptor for TLR4 binding of LPS 
(182), TLR4 endocytosis (183), and for TLR2 by enhancing ligand specificity 
(184,185,186) and endosomal NF-𝜅B signaling (187). CD14’s role in T3S system needle 
protein TLR activation remains unclear. Here we show that blocking CD14 on HEK-Blue 
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TLR2 cells significantly reduced NF-𝜅B/AP-1 activation by T3S system needle proteins 
(Fig 14A). Blocking both CD14 and MD2 in HEK-Blue TLR4 cells inhibited NF-𝜅B/AP-1 
signaling induced by T3S system needle proteins (Fig 14B). HEK-Blue TLR2 cells only 
express CD14, while HEK-Blue TLR4 cells express MD2 in addition to CD14 so both 
blocking antibodies were required to block activation in the HEK-Blue TLR4 cells. These 
data suggest CD14 as an important co-receptor in TLR2 and TLR4 activation by T3S 
system needle proteins. CD14 has been shown to act as a co-receptor for both TLR7 and 
TLR9 (40), in addition to working in combination with TLR2 and TLR4 (201,202). At this 
point it is unclear if CD14 is augmenting T3S system needle protein NF-𝜅B/AP-1 by 
facilitating receptor internalization. It is possible that CD14 might be enhancing TLR 
binding by T3S system needle proteins.  
 In conclusion, we demonstrate that T3S system needle proteins activate NF-
𝜅B/AP-1 and induce TNF-𝛼 release mediated by clathrin/dynamin-regulated receptor 
endocytosis and CD14 (Fig 16). Given the immune stimulating properties of T3S system 
needle proteins, they have potential as vaccine adjuvants, and further understanding 
their signaling mechanisms will serve as the groundwork for future vaccine 
development.  
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Figure 11. Endocytosis inhibitors reduce NF-𝜿B/AP-1 signaling induced by T3S system 
needle proteins in HEK-Blue TLR2 and HEK-Blue TLR4 cells. HEK-Blue TLR2 and HEK-Blue 
TLR4 cells were treated with CPZ (A,D), CHQ (B,E), and Dyn (C,F) at concentrations 
indicated in the figure for 1 hour prior to T3S system needle protein stimulation. Cells 
were stimulated with 1 𝜇g/ml of T3S system needle protein, 100 ng/ml of Pam3CSK4, or 
1 ng/ml LPS for 24 hours and NF-𝜅B/AP-1 activation was measured by SEAP production 
read at 630nm. Data are presented as mean ± SE of triplicate wells, and are 
representative of at least 3 independent experiments. * Indicates p is between 0.05 and 
0.01; ** Indicates p is between 0.01 and 0.001; *** Indicates p is between 0.001 and 
0.0001; **** Indicates p < 0.0001. 
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Figure 12. Endocytosis inhibitors reduce TNF-𝜶 production in T3S system needle 
protein human THP-1 cells. Human THP-1 cells were treated with (A) CPZ, (B) CHQ, or 
(C) Dyn for 1 hour prior to T3S system needle protein stimulation. Cells were stimulated 
with 1 𝜇g/ml of T3S system needle protein, 100 ng/ml of Pam3CSK4, or 1 ng/ml of LPS 
for 24 hours. Release of TNF-𝛼 was measured in the cell culture supernatant by ELISA. 
Data are presented as mean ± SE of triplicate wells and are representative of at least 3 
independent experiments. * Indicates p is between 0.05 and 0.01; ** Indicates p is 
between 0.01 and 0.001; *** Indicates p is between 0.001 and 0.0001; **** Indicates p 
< 0.0001. 
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Figure 13. siRNA gene knockdown of heavy chain clathrin reduced NF-𝜿B/AP-1 
signaling induced by T3S system needle proteins in HEK-Blue TLR2 cells. (A) HEK-Blue 
TLR2 and (B) HEK-Blue TLR4 cells treated with 1 µM Accell siRNA against heavy chain 
clathrin 17 (grey bars) designed by supplier or with 1 µM of non-targeting siRNA (closed 
bars). After 24 h, complete DMEM was supplemented to the wells and transfection 
continued for a total of 72 h. Following transfection, cells were stimulated with 1 𝜇g/ml 
of T3S system needle protein, 100 ng/ml Pam3CSK4, or LPS for 24 hours. NF-𝜅B/AP-1 
activation was measured by quantification of SEAP by reading the absorbance at 630 
nm. Data are presented as mean ± SE of triplicate wells and are representative of 2 
independent experiments. * Indicates p is between 0.05 and 0.01; ** Indicates p is 
between 0.01 and 0.001.       
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Figure 14. CD14 mediates NF-𝜿B/AP-1 signaling induced by T3S system needle 
proteins in HEK-Blue TLR2 and HEK-Blue TLR4 cells. (A) HEK-Blue TLR2 cells were 
treated with 10 𝜇g/ml of anti-CD14 antibody (grey bar), 10 𝜇g/ml of isotype control 
antibody (white bar), or no antibody (closed bar) prior to T3S system needle protein 
stimulation. (B) HEK-Blue TLR4 cells were treated with 10 𝜇g/ml of both anti-CD14 and 
anti-MD-2 (grey bar), isotype control antibody (white bar), or no antibody (closed bar) 
prior to T3S system needle protein stimulation. NF-𝜅B/AP-1 activation was measured by 
quantification of SEAP by reading the absorbance at 630 nm. Data are presented as 
mean ± SE of triplicate wells and are representative of at least 3 independent 
experiments. * Indicates p is between 0.05 and 0.01; ** Indicates p is between 0.01 and 
0.001; *** Indicates p is between 0.001 and 0.0001; **** Indicates p < 0.0001.     
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Figure 15. Direct cell cytotoxicity of endocytosis inhibition in HEK-Blue TLR2 and HEK-
Blue TLR4 cells. (A) HEK-Blue TLR2 and (B) HEK-Blue TLR4 cells were treated with the 
highest and lowest concentration of each inhibitor and LDH release was measured as a 
cell cytotoxicity measure. % cell viability was calculated from non-treated cells. Data a 
presented as mean ± SE of triplicate wells and are representative of 2 independent 
experiments. *** Indicates p is between 0.001 and 0.0001; **** Indicates p < 0.0001.        
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
 
 
 
 
 
 
Figure 16. Proposed model of T3S system needle protein endosomal activation of NF-
𝜿B/AP-1 and pro-inflammatory release. T3S needle proteins are recognized by TLR2 
and TLR4 on the surface of innate cells and can be internalized by clathrin-mediated 
endocytosis. This internalization augments T3S needle protein-induced NF-𝜅B/AP-1 
activation through endosomal signaling, resulting in inflammatory cytokine release.  
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CHAPTER IV 
 
BSCF AS A VACCINE CANDIDATE FOR A NEXT GENERATION BORDETELLA PERTUSSIS 
ACELLULAR VACCINE 
 
Introduction 
 
Bordetella pertussis is a gram-negative bacterium and the causative agent of the 
toxin-mediated disease whooping cough (pertussis). Despite widespread vaccination, 
pertussis kills roughly 200,000 infants worldwide, mainly in developing countries. 
Pertussis is characterized by airway inflammation and severe coughing episodes, 
followed by the characteristic “whooping” sound. Pertussis cases are most commonly 
found in infants and young children, however adolescents and adults can also be 
infected. B. pertussis attaches to ciliated epithelial cells in the respiratory tract (51,203). 
Although traditionally thought of as an extracellular pathogen, B. pertussis has been 
shown to invade and reside within epithelial cells and alveolar macrophages (23,24). 
With the advent of a whole cell pertussis (wP) vaccine in the 1940/1950s, cases of 
pertussis were dramatically reduced. Effectiveness of the wP vaccine has been largely 
attributed to its many antigens and PAMPs that bind and activate innate PRRs. The wP 
vaccine proved to be too reactogenic and was replaced with a less reactogenic, subunit 
acellular pertussis (aP) vaccine in the 1990s. The aP vaccine does not contain classical 
PAMPs. The introduction of the aP vaccine was accompanied by a resurgence of 
pertussis cases in both developed and developing countries (88). Given the contribution 
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of the many PAMPs to the effectiveness of the wP vaccine, we propose that the 
addition of PRR stimulating agents could enhance the effectiveness of the current aP 
vaccine. 
 There are a number of contributing factors that have lead to a resurgence of 
pertussis cases attributed to deficiencies in the aP vaccine. First, many circulating 
isolates of B. pertussis have been shown to be deficient in the protective antigens 
included in the aP vaccine; namely pertussis toxin (PT), pertactin (Prn) and fimbriae 
(Fim2 and Fim3) (103,134,135,76,136). In addition, a B. pertussis strain lacking Prn and 
PT was recently isolated from an unvaccinated infant in the United States (136). Due to 
the lack of these key antigens, it is possible that the aP vaccine is not providing robust 
immune responses against many currently circulating pertussis strains. Second, many 
studies have demonstrated that the aP vaccine does not elicit effective immunological 
memory (137,138,139,140). This lack of long-term immunity is particularly concerning 
because small infants that are most susceptible to severe symptoms of pertussis rely on 
herd immunity. This incomplete immunity results in adults spreading pertussis to 
infants, despite the adults receiving the full immunization schedule. 
 Finally, the current aP vaccine does not elicit strong immune responses that are 
necessary for long-term protection (86,113). The aP vaccine has been shown to prevent 
clinical pertussis symptoms, but the aP vaccine may not prevent bacterial colonization 
or transmission (113). Requirements for the correct type of immune responses needed 
to be effective against B. pertussis are evident in natural infections of B. pertussis. 
Athymic nu/nu mice, which lack all T cells, are unable to clear a B. pertussis infection 
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(84,85)and adoptive transfer of total splenic T cells into athymic mice was able to 
prevent chronic infection in nu/nu mice.  Transfer of only B. pertussis specific CD8+ T 
cells was not able to reverse chronic infection, indicating a critical role for CD4+ T cells in 
controlling B. pertussis infections (85). CD4+ T cells collected from the draining lymph 
nodes of B. pertussis infected mice produce high levels of interferon gamma (IFNy), a 
prototypical T helper cell (Th) Th1-type cytokine, with little interleukin-4 (IL-4), a 
prototypical Th2-type cytokine (85). In addition, IFNy mRNA levels in the lungs increased 
sharply during the first week of infection (85), suggesting a protective role for IFNy and 
CD4+ Th1 cells. The contribution for Th17 cells was demonstrated by persistent lung 
colonization with B. pertussis in IL-17-/- mice (86). The lack of IL-17 and persistent 
infection was correlated with a decrease in neutrophil recruitment into the lungs 
(86,204,123). Both Th1 and Th17 cells have shown to be important in humans as well. 
wP vaccines have been shown to induce predominately mixed Th1/Th17 type CD4+ T cell 
responses in children, similar to natural infection (114,144,205) In terms of humoral 
immunity, B cells appear to play an auxiliary role, potentially by activating the adaptive 
immune response (206,207). These studies highlight the importance of both Th1 and 
Th17 cells in protective immunity induced by a natural B. pertussis infection. 
In contrast to a natural infection with B. pertussis or the wP vaccine, the aP 
vaccine has been shown to have distinct immune stimulating properties, likely 
contributing to the current resurgence of pertussis cases. In humans, aP vaccination has 
been shown to induce a robust Th2 response, with minimal Th1/Th17 CD4+ T cell 
responses (114,142,117). Mouse studies also identify a strong Th2 and a Th17 response 
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generated by the aP vaccine. aP vaccination is associated with CD4+ T cells that produce 
IL-4, interleukin-5 (IL-5), and interleukin-17 (IL-17), but little IFNy (86,123). The 
protective immunity generated by the aP vaccine was shown to be mediated through 
Th17 cells, while the Th2 cells appear to be unnecessary (86). In addition, the ability of 
the aP vaccine to provide protection for long periods of time has been called into 
question. aP vaccination promoted differentiation of B. pertussis specific terminally 
differentiated T cells (TTD) over central memory T cells (TCM) (208). In addition, two years 
after vaccination, peripheral blood mononuclear cells (PBMCs) from children that 
received the aP vaccine produced lower levels of B. pertussis specific IL-17 compared to 
PBMCs from wP vaccinated children (117). It is clear that the aP vaccine elicits sub-
optimal immunity, and with the resurgence of pertussis cases, the need for a next-
generation pertussis vaccine is apparent.  
As mentioned above, the numerous PAMPs associated with the wP vaccine 
significantly enhanced its effectiveness. These endogenous PAMPs activate the innate 
immune system through PRRs – specifically Toll-like receptors (TLRs), promote pro-
inflammatory cytokine release, and direct pertussis-specific adaptive immunity (118). 
Because PAMPs appear to be an important aspect of the wP vaccine, it has been 
suggested that the addition of TLR agonists to the aP vaccine could re-direct the 
immune response generated by the aP vaccine to a more wP-like immune response. A 
TLR2 agonist of B. pertussis when combined with the components of the aP vaccine 
enhanced protection from an aerosol B. pertussis challenge, induced robust IgG2a 
antibodies, and enhanced IL-17 and IFNy production from antigen stimulated 
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splenocytes ex vivo compared with the aP vaccine in alum (120). A TLR4 agonist, 
monophosphoryl lipid A (MPL), when mixed with the aP vaccine increased protection 
against B. pertussis challenge when compared with the aP vaccine in alum adjuvant, 
while suppressing Th2 responses (121). A separate TLR agonist, LpxL1 (122), a 
genetically engineered LPS from Neisseria meningitidis, enhanced antigen specific IFNy 
and IL-17 CD4+ T cells and increased the number of specific memory CD4+ TCM cells when 
added to the aP vaccine (123). Finally, CpG oligonucleotides from bacterial DNA that 
activate TLR9 have been shown to induce antigen-specific IgG2a titers (124) and Th1 and 
Th17 cells (125) when added to the aP vaccine (86). These studies show the feasibility 
and effectiveness of incorporating novel TLR agonists into the aP vaccine to enhance 
pertussis specific immunity that will not only promote the proper adaptive immune 
responses, but could also augment the long-term efficacy of the aP vaccine.  
We have recently identified that needle proteins from bacterial type III secretion 
(T3S) systems are novel TLR agonists that activate TLR2 and TLR4, promote 
inflammatory cytokine release, and can be modified to modulate TLR signaling 
(130,131). In addition, we have also characterized the innate stimulating properties of 
BscF, a purified T3S system needle protein from B. pertussis (unpublished results). In the 
current study, we investigated the contribution of BscF when added to a laboratory 
prepared aP vaccine. We demonstrate that BscF’s ability to engage TLRs has the 
potential to enhance aP induced vaccine immunity to generate long lasting protective 
immunity against B. pertussis.  
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Materials and Methods 
 
Bacterial strains and growth conditions 
 E. coli Novablue (EMDMIllipore, Billerica MA), BL21 (DE3) star (Invitrogen, 
Carlsbad, CA), TOP10 (Invitrogen), and Bordetella pertussis (Tohama I, ATCC BAA-589 
and 12743, ATCC 5375[3865]) were stored at -80°C in 25% glycerol (vol/vol). E. coli 
strains were grown at 37°C in LB broth (BD, Franklin Lakes, NJ) or on tryptose blood agar 
base (TBA, BD) plates, with kanamycin (50 µg/ml) as needed. B. pertussis was 
maintained as previously described (162). Briefly, B. pertussis was grown at 37°C on 
Bordet-Gengou (BG) solid medium (RemelTM Thermo Fisher Scientific, Lenexa, KS) 
supplemented with glycerol and 15% sterile sheep’s blood (Lampire Biological Labs, 
Pipersville, PA). B. pertussis liquid cultures were grown in Stainer-Scholte broth 
supplemented with heptakis (2,6-di-O-methyl-ß-cyclodextrin; Sigma-Aldrich, St. Louis, 
MO) and Stainer-Scholte supplements at 37°C. In the case of the GFP-expressing 
pertussis, both solid and broth medium were supplemented with kanamycin (50 µg/ml) 
and gentamicin (30 µg/ml).    
Expression and purification of His-tagged recombinant proteins 
 Template DNA for amplification was generated by using a DNeasy kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. Oligonucleotide primers 
(Eurofins MWG Operon, Inc. Huntsville, AL) were used to amplify BscF DNA from B. 
pertussis Tohama I strain: BscF forward (5’-CAC CAT GGC CAT TAA CCT GGG AGG-3’) and 
BscF reverse (5’-TCA ACT CGC CTT CTG TAT GAC GCC C-3’). PCR was performed using Pfu 
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Ultra polymerase (Agilent Technologies, Santa Clara, CA). The amplified DNA was cloned 
in frame with a N-terminal His-tag into pET200 by using a Champion TOPO expression kit 
(Invitrogen). Plasmid for protein expression was purified from E. coli TOP10 with a 
Qiaprep Miniprep kit (Qiagen). Purified plasmid DNA was then transformed into 
chemically competent E. coli BL21 (DE3) Star (Invitrogen). Plasmid construct was verified 
by sequencing (Eurofins MWG Operon, Inc.).  
 Protein purification was performed as previously described (130,131). Briefly, E. 
coli BL21 (DE3) Star (Invitrogen) was grown overnight at 37°C in a shaking water bath in 
non-inducing medium (50X M, 1 M MgSO4, 40% glucose, 5% aspartic acid (163)) 
supplemented with antibiotic. Bacteria were then inoculated into auto-inducing medium 
(50X M, 1 M MgSO4, 50X 5052, NZ-amine S, yeast extract, distilled water (163)) 
supplemented with antibiotic and grown to an A620 of 0.6 to 0.8. Cells were harvested by 
centrifugation at 4,000 x g for 10 min at 4°C and resuspended with wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10% glycerol (wt/vol)). The bacterial suspension was then 
French pressed at 20,000 lb/in2 twice to lyse cells. The lysate was centrifuged at 10,000 
x g for 20 min at 4°C. The supernatant was collected and diluted with 1,000 ml of wash 
buffer before application to a pre-equilibrated TALON metal affinity resin (Clontech, 
Mountain View, CA) column. The lysate was applied to the column twice followed by 
washing the column with 15 bed volumes of wash buffer. Bound protein was eluted in 
elution buffer (50 mM NaH2PO4, 200 mM NaCl,150 mM imidazole, and 20% glycerol 
(wt/vol)). Purified protein was concentrated by centrifugation (Amicon Ultra centrifugal 
filters, Millipore, Billerica, MA), and dialyzed against phosphate-buffered saline (PBS) 
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plus 10% glycerol (wt/vol) in Slide-A-lyzer dialysis cassettes (Pierce, Thermo Fisher 
Scientific, Rockford, IL). Protein concentration was determined by Bradford protein 
assay (Pierce, Thermo Fisher Scientific), and purified protein was stored at -80°C for 
future use.  
Bone marrow derived cell isolation and differentiation 
 Bone marrow cells were collected from femurs of WT naïve mice. Femurs were 
aseptically removed from each hind leg, briefly soaked in 70% ethanol, and placed in 
fresh RPMI medium (10% heat inactivated FBS, 2 mM L-glutamine, 50 mM 2-
mercaptoethanol, and 50 µg/ml Pen-Strep). Both ends of the femur were cut and the 
bone was flushed with 10 ml of RPMI and the cells were collected in a 50 ml conical 
tube. The cell suspension was centrifuged at 400 x g for 10 min at 4°C. The cells were 
resuspended in RPMI supplemented with 40 ng/ml granulocyte-macrophage colony-
stimulating factor (GMCSF; PeproTech, Rocky Hill, NJ), seeded at a density of 4 X 106 in 
20 ml of medium in a 150 x 20 mm round culture dish, and incubated at 37°C with 5% 
CO2. On day 3, the cells were supplemented with 20 ml of fresh RPMI + 40 ng/ml GMCSF 
and incubated for an additional 3 days. At day 6, the non-adherent cells were removed 
(BMDCs), and were used for subsequent analysis.  
Innate cytokine analysis and maturation assessment of BMDCs 
BMDCs were seeded in triplicate at 1 X 106 cells/ml into 24-well plates and 
stimulated with 1 µg/ml of needle protein for 24 h at 37°C with 5% CO2. PBS, 1 µg/ml 
LPS (E. coli K12; InvivoGen), and/or 1 µg/ml Pam3CSK4 (InvivoGen) were used as 
negative and positive controls. Following stimulation, cells were centrifuged at 400 x g 
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for 5 min at 4°C and the cellular supernatant was removed and stored at -20°C for future 
analysis. Numerous human and mouse innate cytokines were measured by DuoSet 
enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems (Minneapolis, MN) 
or mouse inflammation panel cytometric bead analysis (CBA) kit (BioLegend, San Diego, 
CA). CBA samples were collected by flow cytometer (LSR II, Becton Dickinson, San Jose, 
CA), and analyzed by software provided by the manufacturer (LEGENDplex v7.0). For 
BMDC maturation analysis, the stimulated cells were collected and surface stained for 
antibodies specific for MHCII, CD80, and CD86. Surface expression and activation 
markers were analyzed by flow cytometry (LSR II, Becton Dickinson, San Jose, CA).     
Mouse immunization and intranasal B. pertussis challenge 
 6-8 week old C57BL/6 male mice were immunized intra peritoneally with 100 µL 
of a laboratory prepared aP vaccine composed of 0.5 µg mutant PT (genetically 
inactivated by site-directed mutagenesis (R9K) and (E129A) in the S1 subunit; List 
Biological Laboratories, Campbell, CA), 1 µg FHA (List Biological Laboratories, Campbell, 
CA) mixed with PBS (aP + PBS) or 40 µg purified BscF (aP + BscF). Mice were boosted at 4 
weeks with the same components. Mice that received PBS injections served as controls. 
Two weeks after the last immunization, mice were intra nasally challenged with 6 X 106 
CFU of B. pertussis 12743 in a 25 µl inoculum. 7 d post infection, lungs were aseptically 
removed, and homogenized (Bullet blender, Next Advance, Averill Park, NY) in 1 ml of 
sterile PBS. Lung homogenate was centrifuged at 130 x g for 1 min at 4°C, serial dilutions 
were plated on 15% blood BG plates, and incubated at 37°C for 4-5 d. Lung bacterial 
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burden was determined by counting CFUs. All animal experiments were approved by 
IACUC at the University of North Dakota. 
ELISA assay of antibody levels in mouse serum 
 ELISA plates (Costar EIA/RIA, Corning) were coated with 100 µl of 1 µg/ml mPT or 
FHA diluted in PBS and incubated overnight at 4°C. Plates were washed with wash buffer 
(1X PBS, 0.05% Tween-20), and blocked with blocking buffer (1X PBS, 1% BSA, 0.05% 
Tween-20) and incubated at room temperature for 1 h. Plates were again washed and 
incubated with diluted mouse serum for 1 h at room temperature. Following incubation, 
plates were washed, blocked for 10 min at room temperature with blocking buffer, and 
incubated with rabbit anti-mouse IgG biotinylated (Invitrogen) antibody diluted 
1:10,000 in blocking buffer for 1 h at room temperature. Both wash and blocking steps 
were repeated as indicated above, and plates were incubated with streptavidin-HRP 
(Invitrogen) diluted 1:2,000 in blocking buffer for 1 h at room temperature. For 
measuring IgG isotypes, isotype specific goat anti-mouse IgG1, and IgG2c, (Sigma-
Aldrich) diluted 1:1,000 in blocking buffer was incubated following diluted serum for 30 
min at room temperature. Plates were washed and blocked as indicated above, and 
bound IgG was detected with biotinylated rabbit anti-goat IgG (Sigma-Aldrich) for 30 
min at room temperature. Plates were again washed and blocked, and incubated with 
streptavidin-HRP (Invitrogen) diluted 1:2,000 in blocking buffer for 30 min at room 
temperature. Plates were washed with wash buffer and incubated with 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate for 10 min at room temperature. The reaction 
was stopped by adding 50 µl of 1 M H2SO4. Optical densities (OD) were measured at 450 
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nm with a microplate reader (Synergy HT, BioTek) and were analyzed with KC4 v3.3 
software (BioTek). IgG was quantified by reading absorbance at 450 nm, correcting for 
the background (day 0 serum).  
T cell cytokine production 
 At 2 weeks post last immunization, spleens were collected from mice receiving 
either PBS, aP+PBS, or aP+BscF, and processed to a single cell suspension. Following red 
blood cell lysis, splenocytes were suspended in RPMI (10% heat inactivated FBS and 50 
µg/ml of Pen-Strep) and seeded at 2 X 106 cells/ml into 24 well plates. Splenocytes were 
stimulated with 1 µg/ml purified mPT, FHA, BscF, or medium alone as negative control 
for 72 h at 37°C with 5% CO2. Plates were centrifuged at 400 x g for 5 min at 4°C and 
cellular supernatant was removed. IFN-y and L-17A production was determined by 
DuoSet ELISA kits (R&D Systems). 
Characterization of T cell response and T cell memory induced by aP vaccination 
 At 2 weeks post last immunization, spleens, inguinal lymph nodes, and blood 
were collected. Splenocytes were prepared to single cell suspension as indicated above. 
Lymph nodes were homogenized and prepared to a single cell suspension in complete 
RPMI medium. 100 µl of blood from each mouse was used for staining and subsequent 
analysis with the remaining blood being processed for serum and stored at -80°C. 1-
2x106 splenocytes and lymphocytes as well as 100 µl of blood were stained with anti-
mouse CD3, CD4, CD8, CD44, and CD62L for 30 minutes at room temperature. Blood 
samples were incubated with red blood cell lysis buffer for 10 minutes at room 
temperature. The cells were washed 2 times and suspended in flow cytometry staining 
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buffer (2% FBS 1X PBS). Data were collected by flow cytometer (LSR II, Becton Dickinson, 
San Jose, CA) and data were analyzed by FlowJo (FlowJo, LLC, Ashland, OR). The 
following gating scheme was used to identify the populations of CD4+ and CD8+ T cells: 
The first gate was on the cell population using SSC-A (cell complexity) vs FSC-A (cell size). 
From there, singlets were identified by FSC-W (cell width), and the population of CD3+ 
cells was identified. Within the CD3+ population, a quadrant gate of CD4 and CD8 was 
used to identify CD4+ and CD8+ cells. To identify naïve, memory (Tcm) and effector (Tem) T 
cell subsets, cells and singlets were identified as indicated above. Within the singlets 
population, a quadrant gate was used to identify either CD3+CD4+ or CD3+CD8+ T cells. 
Within those populations a combination of CD62L and CD44 was used to identify naïve T 
cells (CD62L+CD44low), Tcm (CD62L
highCD44int-high), and Tem (CD62L
negCD44high). Refer to 
Figure 20 for a demonstration of the gating scheme.    
Statistical analysis 
Data were assembled into graphs using GraphPad Prism, version 5.0f (GraphPad 
Software, La Jolla, CA). Data were analyzed using one-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison test. Differences were considered statistically 
significant when p<0.05. 
 
Results 
 
BscF promotes DC maturation and inflammatory cytokine release 
 
 Since we have demonstrated that a number of T3S system needle proteins are 
potent TLR agonists and induce inflammatory cytokine release from innate cells, we 
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examined the ability of BscF to activate mouse DCs in vitro. BscF stimulation for 24 
hours promoted bone marrow derived DC maturation as measured by increased surface 
expression of MHC class II, and the co-stimulatory molecules CD80, and CD86 (Fig 17A-
C). BscF stimulation also produced robust IL-6, TNF-𝛼, IL-1𝛽, and IL-12p40 release, 
accompanied by a modest increase in IL-23 production (Fig 17D-F). These data indicate 
that BscF is a TLR agonist and activates murine DC maturation and cytokine release in 
vitro.  
BscF is immunogenic in vivo and act as an adjuvant when added to a laboratory 
prepared aP vaccine 
 
 Having shown that BscF promotes inflammatory cytokine release by murine DCs 
in vitro, we assessed BscF’s in vivo adjuvant capability when added to a laboratory 
prepared aP vaccine. 6-8-week-old C57BL/6 male mice were immunized intra 
peritoneally with 100 µL of a laboratory prepared aP vaccine composed of 0.5 µg mPT 
and 1 µg FHA diluted in PBS (aP + PBS), or supplemented 40 µg purified BscF (aP + BscF). 
Mice were boosted at 4 weeks with the same components. At 6 weeks post first 
vaccination, antibody characterization was performed for both antigen specific IgG as 
well as isotype antibody analysis. The addition of BscF (aP + BscF) to the aP vaccine 
significantly increases FHA specific total IgG responses (Fig 18A). BscF did not 
significantly enhance mPT specific total IgG responses (Fig 18D). FHA specific IgG1 as 
well as IgG2c isotypes were significantly increased in the aP + BscF group when 
compared to the aP + PBS (Fig 18B-C). mPT specific IgG1 and IgG2c isotypes were not 
increased by the addition of BscF to the laboratory aP vaccine (Fig 18E-F). These data 
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demonstrate that BscF can enhance the aP vaccine specific antibody immune response 
generated by a laboratory prepared aP vaccine.  
BscF indirectly enhances IFN-𝜸 and IL-17 production by stimulated splenocytes in vitro 
 We have shown that BscF promotes inflammatory cytokine release by murine 
DCs, including IL-6, IL-12, and IL-23. These cytokines are associated with the expansion 
of Th1 and Th17 cells. To further characterize the immune modulating properties of 
BscF when included in our laboratory prepared aP vaccine, splenocytes from mice 
immunized with either aP + PBS, aP + BscF, or PBS were processed to a single cell 
suspension and stimulated with each antigen, including BscF in vitro. The addition of 
BscF to the aP vaccine significantly increased IFN-𝛾 from FHA stimulated splenocytes, 
when compared to the aP + PBS (Fig 19A). Interestingly, IL-17 release was more robust 
in the aP + PBS group when stimulated with FHA (Fig 19B). aP + BscF splenocytes 
stimulated with mPT as well as BscF produced significantly more IFN-𝛾 when compared 
to aP + PBS splenocytes (Fig 19A). IL-17 release did not differ between groups when 
stimulated with mPT; however, BscF stimulated aP + BscF splenocytes produced robust 
IL-17 release whereas no detectable levels were reported in the aP + PBS group (Fig 
19B). These data suggest that BscF’s immune stimulating properties indirectly enhanced 
our aP vaccine immune responses in vivo.    
BscF modulates memory response generated by the aP vaccine 
 We next assessed the ability of BscF to influence the long-term immunity 
generated by our laboratory aP vaccine. CD4+ and CD8+ T cells within the blood (data 
not shown), spleen, and inguinal lymph nodes were investigated ex vivo based on CD62L 
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and CD44 expression within a population of CD3+CD4+ or CD3+CD8+ subsets following 
vaccination. Within those populations a combination of CD62L and CD44 was used to 
identify naïve T cells (CD62L+CD44low), Tcm (CD62L
highCD44int-high), and Tem 
(CD62LnegCD44high) as indicated in Figure 20. Total CD4+ and CD8+ T cells were increased 
in the lymph nodes in aP + BscF mice compared to aP + PBS mice (Fig 20A,E). 
Interestingly, naïve CD8+ T cells, but not CD4+ T cells within the lymph nodes were 
increased in the BscF group (Fig 20B,F). Tem cells were not increased in either 
compartment by the addition of BscF (Fig 20C,G). aP + BscF significantly enhanced both 
CD4+ and CD8+ Tcm cells within the lymph nodes when compared to the aP + PBS group 
(Fig 20D,H). These results indicated that the addition of BscF to the aP vaccine induced 
CD4+ and CD8+ T cells, but also enhanced a central memory T cell phenotype, potentially 
indicating improved long term immunity generated by the aP vaccine with BscF.  
The addition of BscF to our laboratory aP vaccine promotes protective immunity 
against a sub lethal B. pertussis challenge   
 
 Mice were immunized with either aP + PBS, aP + BscF, or PBS as indicated above. 
At 6 weeks post vaccination mice were challenged intranasally with live B. pertussis and 
lungs were harvested 7 days post infection, homogenized in 1 mL of sterile saline, and 
plated to enumerate CFU in the lungs. PBS control mice were well colonized with B. 
pertussis at 7 days post infection (Fig 21). Immunization with aP + PBS provided modest 
protection when compared to non-immunized mice (Fig 21). In contrast, mice 
immunized with aP + BscF demonstrated enhanced bacterial clearance when compared 
to both non-immunized mice as well as aP + PBS mice (Fig 21). These data demonstrate 
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the adjuvant properties of BscF when included in our laboratory aP vaccine by increased 
bacterial clearance in the aP + BscF mice.    
Discussion 
 
 In the current study, we characterized a novel TLR ligand from the T3S system 
needle complex of B. pertussis that activates the innate immune system to enhance 
protective immunity generated by our laboratory prepared aP vaccine. This protein, 
BscF, has been shown to activate TLR2 and TLR4, induce intracellular NF-𝜅B/AP-1 
signaling, and promote inflammatory cytokine release from innate cells in vitro [current 
study and unpublished results]. The ability of BscF to engage multiple TLRs is in line with 
other purified T3S system needle proteins that we have previously characterized 
(130,131). BscF demonstrated potent immune modulating activities in vitro, driving 
murine dendritic cell (DC) maturation and inflammatory cytokine production. The 
addition of BscF to the laboratory prepared aP vaccine enhanced vaccine-specific IgG 
responses, indirectly induced Th1 and Th17 responses in ex vivo stimulated splenocytes, 
and provided enhanced protection against B. pertussis challenge.    
 The importance of generating cellular immunity, specifically Th1 and Th17 cells 
has been highlighted in both natural and vaccine-induced immunity 
(86,84,85,114,141,143). One of the inadequacies of the current aP vaccines is the lack of 
innate immune stimulating properties necessary to effectively induce protective cellular 
immunity. The wP vaccine was considered a strong Th1 producing vaccine due to its 
numerous endogenous pathogen associated molecular patterns (PAMPs) that engaged 
numerous pattern recognition receptors (PRRs), significantly enhancing its effectiveness 
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at generating protective immunity (118). We demonstrated that BscF has strong innate 
immune stimulating properties and matures murine DCs as measured by inflammatory 
cytokine release IL-12, IL-6, IL-23, and IL-1𝛽, and surface expression of prototypical 
maturation markers. Expansion of Th1 and Th17 cells is influenced by the presence of 
these innate cytokines (209). Due to the immune modulating properties of BscF, we 
suggest that the addition of BscF to the aP vaccine may promote Th1 and Th17 
responses and drive protective immunity.    
 Current literature has exploited a host of PRR stimulating agents in combination 
with current aP vaccines to drive protective Th1 and Th17 responses that are generally 
lacking with aP vaccination. Unlike natural B. pertussis infection or vaccine induced 
immunity generated by the wP vaccine, the current aP vaccine in alum adjuvant 
preferentially induces Th2-type responses (86,123,114,142,117). These stimulating 
agents include TLR2 agonists (120), TLR4 agonists (123,121,122), and TLR9 agonists 
(86,124,125). Interestingly, many of these agonists have proven effective at skewing the 
aP vaccine-induced immunity to a more effective wP-like immune response by 
increasing IgG2a antibody production, expanding Th1 and Th17 cellular immunity, and 
providing enhanced protection from B. pertussis infections in mice. In the current study, 
we report enhanced pertussis specific antibody titers, including the Th1 indicating IgG2c 
isotype, when our novel T3S system needle protein, BscF, was included in our laboratory 
prepared aP vaccine. Additionally, BscF indirectly enhanced Th1 and Th17 cytokine 
production from ex vivo stimulated splenocytes.  
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 Another limitation to the current aP vaccines absorbed in alum adjuvant is the 
lack of long-lasting immunological memory (137,138,139,140). Waning immunity, in 
addition to other factors, may be contributing to the rise in whooping cough cases 
despite relatively high vaccination rates. Brummelman et al., demonstrated that the 
addition of a TLR4 ligand to the aP vaccine resulted in an increased pertussis-specific Tcm 
phenotype, suggesting enhanced long-term efficacy of the vaccine (123). The generation 
of Tcm cells is a good predictor of long-term immunity (210,211,212,213). Here we report 
that the addition of BscF to the aP vaccine increased CD4+ and CD8+ T cells within the 
inguinal lymph nodes when compared to the aP vaccine in PBS. In addition, Total CD4+ 
Tcm and CD8
+ were increased in the presence of BscF. These data provide evidence of 
BscF’s ability to modulate vaccine induced immunity. It is worth noting that we did not 
use any methods necessary to assess pertussis-specific memory T cells. This study differs 
from Brummelman et al., who utilized MHC class II tetramer analysis to identify 
pertussis-specific CD4+ T cells (123).  
 Although aP vaccine has been able to prevent clinical pertussis symptoms, it did 
not reduce bacterial colonization of transmission in baboons (113). Here we 
demonstrated the benefit of the immune modulating capacity of BscF to enhance 
bacterial clearance of the aP vaccine. This benefit is likely the result of BscF promoting 
protective cellular immunity through its innate stimulating properties. Taken together, 
our results demonstrate that BscF, a purified T3S system needle protein from B. 
pertussis has potential to improve aP vaccine-induced immunity by indirectly promoting 
protective cellular immunity through its TLR stimulating properties. BscF has been 
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shown to promote inflammatory cytokine release from human cells (unpublished data), 
suggesting the immune modulating capacity of BcsF may extend to humans as well. In 
addition, mice immunized with BscF prior to B. pertussis challenge had modest 
reductions in lung bacterial burdens compared to non-immunized mice (unpublished 
data). Given the extracellular localization of BscF on the bacterial surface, we believe 
BscF has the ability to act not only as an adjuvant but also as a modest protective 
antigen, thus providing potentially unique advantages over other PRR stimulating 
agents. The need for improved vaccines exists, and BscF may hold potential for inclusion 
in a next-generation B. pertussis vaccine.     
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Figure 17. BscF promotes murine DC maturation and inflammatory cytokine release. 
Murine DCs were stimulated with 1 𝜇g/ml of BscF (solid line) or medium (dashed line) 
for 24 hours. Following stimulation surface expression of (A) MHC class II, (B) CD80, and 
(C) CD86 was determined by flow cytometry. Cell culture supernatant was collected 
following 24 hour stimulation with 1 𝜇g/ml BscF (open bars), 1 𝜇g/ml LPS (positive 
control; grey bars), or medium (negative control; closed bars), and levels of (D) IL-6, (E) 
TNF-𝛼, (F) IL-23, (G) IL-1𝛽, and (H) IL-12p40 were measured by ELISA. Data are 
presented as mean ± SE of triplicate wells and are representative of 2-3 independent 
experiments. * Indicates p is between 0.05 and 0.01. *** Indicates p is between 0.001 
and 0.0001. **** Indicates p < 0.0001.       
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Figure 18. BscF acts as an adjuvant to enhance aP vaccine specific antibody responses. 
Mice were immunized with aP + PBS or aP + BscF twice (0 and 4 weeks), and serum was 
collected at 6 weeks. (A) Total FHA specific IgG or antibody isotype (B) IgG1 and (C) 
IgG2c were measured in serum samples diluted 1:100. Serum mPT specific (D) total IgG, 
(E) IgG1, and (F) IgG2c were determined in serum samples diluted 1:100. Data are 
presented as mean ± SE of OD450nm absorbance readings corrected by non-immunized 
serum, and are compiled from 4 independent experiments. aP + PBS n = 17 and aP + 
BscF n = 18. ** Indicates p is between 0.01 and 0.001. *** Indicates p is between 0.001 
and 0.0001. **** Indicates p < 0.0001.      
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Figure 19. BscF indirectly enhances IFN-𝜸 and IL-17 production from ex vivo stimulated 
splenocytes. Mice were immunized with aP + PBS (grey bars) or aP + BscF (open bars) 
twice (0 and 4 weeks). PBS immunized mice (closed bars) served a naïve control. At 6 
weeks, spleens were harvested and stimulated ex vivo with 1 𝜇g/ml of either FHA, mPT, 
or BscF, and release of (A) IFN-𝛾 and (B) IL-17 was measured in the cell culture 
supernatant following 72 hour stimulation by ELISA. Data presented as mean ± SE of 4 
mice per group, and are representative of 2 independent experiments. * Indicates p is 
between 0.05 and 0.01. ** Indicates p is between 0.01 and 0.001. *** Indicates p is 
between 0.001 and 0.0001.      
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Figure 20. The addition of BscF to the laboratory aP vaccine enhanced a central 
memory T cell phenotype. Mice were immunized with aP + PBS (closed bars) or aP + 
BscF (open bars) twice (0 and 4 weeks). PBS immunized mice (grey bars) served a naïve 
control. The following gating scheme was used to identify the populations of CD4+ and 
CD8+ T cells: The first gate was on the cell population using SSC-A vs FSC-A. From there, 
singlets were identified by FSC-W, and the population of CD3+ cells was identified. 
Within the CD3+ population, a quadrant gate of CD4 and CD8 was used to identify (A) 
CD4+ and (E) CD8+ cells. To identify naïve, memory (Tcm) and effector (Tem) T cell subsets, 
cells and singlets were identified as indicated above. Within the singlets population, a 
quadrant gate was used to identify either CD3+CD4+ or CD3+CD8+ T cells. Within those 
populations a combination of CD62L and CD44 was used to identify (B and F) naïve T 
cells (CD62L+CD44low), (C and G) Tem (CD62L
negCD44high) and (D and H) Tcm 
(CD62LhighCD44int-high). Data presented as mean ±SE of 4 mice per group, and are 
representative of 2 independent experiments. * Indicates p is between 0.05 and 0.01.     
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Figure 21. The addition of BscF to the laboratory aP vaccine enhanced protective 
immunity against a sub lethal B. pertussis challenge. Mice were immunized with aP + 
PBS (squares) or aP + BscF (triangles) twice (0 and 4 weeks). PBS immunized mice 
(circles) served a naïve control. At 6 weeks, mice were challenged with an intranasal 
inoculum of live B. pertussis. Lung homogenate CFU counts were recorded at 7 days 
post infection. Data are presented as mean ± SE of 4-6 mice per group, and are 
representative of 2 independent experiments. * Indicates p is between 0.05 and 0.01. ** 
Indicates p is between 0.01 and 0.001.       
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CHAPTER V 
DISCUSSION 
 Bordetella pertussis, the causative agent of whooping cough, produces 
significant morbidity and mortality worldwide. Because there are no known non-human 
B. pertussis reservoirs, B. pertussis is truly a vaccine preventable disease. Current aP 
vaccines have fallen short over the last 20-30 years or so of their use, partly contributing 
to the reemergence of B. pertussis incidences in a number of developed and developing 
countries. B. pertussis research has been disadvantaged mostly due to the lack of 
suitable animal models; however, much of the work in these animal models on 
understanding B. pertussis pathogenesis and the critical role both the innate and 
adaptive arms of the immune system play in vaccine development have been validated 
in a newly developed baboon model that exhibits clinical symptoms more similar to 
humans. Moreover, human trials examining both the wP and aP vaccine safety and 
immunogenicity have also been instrumental in moving the field forward. From both 
animal and human studies, it is clear that a next-generation aP vaccine is necessary. In 
the studies included here, we characterize the immune stimulating properties of a B. 
pertussis specific protein called BscF, and assess its immune modulating capabilities 
when added to an aP vaccine. 
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 With the replacement of the wP vaccine with aP vaccines in the 1990’s cases of 
B. pertussis have been on the rise in many countries. Waning and ineffective immunity 
generated by the aP vaccine have been, in part, the cause of B. pertussis reemergence. 
While there have been a number of unique approaches in the effort to develop better 
vaccines, a large amount of work has been focused on the use of innate immune 
agonists (specifically TLR agonists) to skew aP vaccine induced immunity from the 
prototypical Th2 responses to protective Th1 and Th17 responses 
(86,120,121,122,123,124,125). These studies have reported success in animal models 
and provide evidence of the feasibility of adding other TLR ligands to a next-generation 
aP vaccine. Recent work from our lab focusing on purified T3S system needle proteins 
has identified a number of novel TLR agonists from a number of Gram-negative bacteria 
(130,31). These proteins are of interest for a number of reasons. First, T3S system 
needle proteins have been shown to be TLR2 and TLR4 agonists. Second, these proteins 
activate MyD88 dependent NF-𝜅B/AP-1 signaling downstream of TLR activation, and 
promote inflammatory cytokine release (130,131). Third, the strength of innate 
activation and inflammatory cytokine release can be modulated by modifying the N-
terminus of the protein (131), allowing great flexibility if using these proteins and their 
immune stimulating properties in newly developed vaccines.  
 In the current studies, we demonstrated that BscF, a purified T3S system needle 
protein from B. pertussis acts as a strong TLR2 and TLR4 ligand. BscF activated NF-
𝜅B/AP-1 signaling and promoted inflammatory cytokine release from both mouse and 
human cells in vitro. It is noteworthy that human cells respond similarly to BscF 
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stimulation when compared to mouse cells, indicating the possibility of the translational 
application of BscF in human aP vaccines. While we have extensively characterized the 
innate stimulating properties of T3S system needle proteins (130,131), to date, the 
contribution of endosomal TLR NF-𝜅B/AP-1 signaling has not been addressed. 
Additionally, clues to the mechanism of how T3S system needle proteins activate TLRs 
warrants further investigation. Clathrin-mediated endocytosis of plasma membrane 
TLRs (specifically TLR2 and TLR4) has been shown to amplify ligand-induced TLR 
signaling from endosomal compartments as well as activate distinct intracellular 
signaling pathways (179,180,181,187). One of the key players in TLR2 and TLR4 
activation, endocytosis, and ligand specificity is CD14 (183,184,185,186,187). Our data 
indicated that clathrin-mediated endocytosis mediated NF-𝜅B/AP-1 activation, and that 
CD14 controls, in part, TLR2 and TLR4 activation. This is the first report demonstrating 
endocytosis of the TLR augments NF-𝜅B/AP-1 signaling by T3S system needle proteins. 
In addition, these data highlight the critical role of CD14 during T3S system needle 
protein activation of TLR2 and TLR4. Understanding the signaling mechanisms leading to 
TLR2 and TLR4 activation by T3S system needle proteins will facilitate their use in 
vaccine development.    
  In addition to TLR activation, we demonstrated that BscF activates the NLRP3 
inflammasome and requires internalization to process pro-IL-1𝛽 into mature IL-1𝛽. It is 
thought that the wP vaccine was effective at driving CD4+ Th1 and Th17 cellular 
immunity primarily through its immune stimulating properties. wP containing PAMPs 
activate the innate immune system and promote inflammatory cytokine release and DC 
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maturation to induce Th1/Th17 cellular immunity (118). In addition, B. pertussis specific 
Th17 cellular protective immunity and effective bacterial clearance were shown to be 
dependent on stimulation of the NLRP3 inflammasome by adenylate cyclase toxin, and 
subsequent IL-1𝛽 release (60). BscF stimulation of mouse DCs resulted in robust IL-12, 
IL-6, IL-23, and IL-1𝛽 release. These cytokines have been shown to be effective at 
polarizing naïve T cells to Th1 and Th17 subsets during antigen presentation.   
 Ex vivo BscF stimulated splenocytes from mice vaccinated with BscF produced 
robust IFN-𝛾 and IL-17 release, indicating a strong Th1 and Th17 adaptive immune 
response in mice immunized with BscF. Mouse and human studies have clearly 
demonstrated the critical role for CD4+ Th1 and Th17 cells in protective immunity 
elicited by natural infection or vaccination (84,85,86,123,204,114,144,205). In addition, 
BscF immunization resulted in a modest, yet significant, reduction of bacterial burden in 
the lungs 7 days post challenge. While BscF vaccinated mice were still highly colonized 
with B. pertussis, these data indicate that BscF may also act as a protective antigen in 
addition to its immune modulating capabilities in a next-generation aP vaccine. We 
believe that the extracellular localization of BscF makes it an ideal therapeutic target.  
Serum from BscF immunized mice was able to significantly enhance B. pertussis 
opsonization and phagocytosis by mouse cells in vitro. It has been demonstrated that 
T3S system needle and translocon proteins act as protective antigens, presumably 
through the generation of a robust antibody response (145,132,146,147,148,149). 
Further work is needed to identify the protective role of BscF specific antibodies during 
a live B. pertussis mouse infection.  
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 Although we saw modest protection in mice vaccinated with BscF alone, we do 
not envision BscF as a stand-alone vaccine for B. pertussis. We next addressed the ability 
of BscF to skew the immune response elicited by aP vaccination to a protective Th1/17 
response by adding BscF to our laboratory prepared aP vaccine containing mPT and FHA. 
Both mPT and FHA are included in any licensed aP vaccine, so our results may provide 
insight for how BscF would work in future aP vaccines. aP vaccination has shown to 
primarily induce Th2 type responses in both animal models and humans 
(84,86,113,114,115). Our results demonstrate that the addition of BscF to the aP vaccine 
induced significantly higher FHA specific antibody titers, and indirectly induced IFN-𝛾 
and IL-17 from ex vivo stimulated splenocytes when compared to the aP vaccine in PBS. 
In addition, bacterial clearance was enhanced by the addition of BscF to the aP vaccine 7 
days post infection in mice compared to the aP vaccine alone. Our results are consistent 
with other studies demonstrating the effectiveness of skewing aP induced immunity to a 
protective Th1 and Th17 response by adding TLR ligands to aP vaccines 
(86,120,121,122,123,124,125). One advantage of BscF compared to the other TLR 
ligands is that BscF is B. pertussis specific, and could therefore be used as a protective 
antigen as well as an adjuvant in next-generation aP vaccines. In addition, given the 
prevalence of new circulating B. pertussis strains that have genetic modifications of 
many common antigens included in the aP vaccines (103,104,105,77,108,109,110), the 
use of new antigens that will likely not be lost by the bacteria would be advantageous. 
B. pertussis mutants of the T3S system demonstrated reduced colonization and induced 
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exacerbated inflammation during infection (83), suggesting that the loss of the T3S 
system due to vaccine pressure is highly unlikely.  
 This work has provided the foundation for future studies to further investigate 
the immune mechanisms mediating BscF’s role during pertussis infections. For example, 
characterizing the role that BscF specific antibodies play during B. pertussis infection 
through passive transfer of BscF immune serum. Second, utilizing MHC class II tetramer 
staining to facilitate our understanding of BscF and pertussis specific CD4+ T cell 
responses during immunization. Third, investigating if BscF is able to provide any cross 
protection to other Bordetella species (i.e. B. bronchiseptica and B. parapertussis). 
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